CUMULATIVE SUPPLEMENT 9
JAN'96-SEP'96

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

Approved drug products with therapeutic equivalence

SUBSCRIBE NOW!

Available in March 1997

New 17th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION
1997

CONTENTS

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Cumulative Supplement 9

SEPTEMBER 1996

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 1996

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 16th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 16th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 17th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval

on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release;transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Propantheline Bromide

In Cumulative Supplement 1 of the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition, (Orange Book), the Agency proposed to change the therapeutic equivalence code for propantheline bromide oral tablets from a drug product not presenting a bioequivalence problem **(AA)** to a drug product with a potential bioequivalence problem **(BP)**.

The Agency solicited comments from interested persons to be received no later than 60 days from the first day of the month following the publication of Cumulative Supplement 1. The proposal did not elicit any comments from the readers. In addition, the two firms who hold an active ANDA and are marketing the drug product were contacted to inform them that the codes for their propantheline drug products were going to be changed. Since there were no comments submitted by the readers or by the two firms who hold an active ANDA, the therapeutic equivalence code for propantheline bromide tablets will be changed to one reflecting a potential bioequivalence problem. Therefore, all oral propantheline bromide tablets will be changed in this month's Cumulative Supplement from **(AA)** to **(BP)** to reflect it has a potential for a bioequivalence problem.

An acceptable *in vivo* bioequivalence study, among other information, will be required to change the code from **(BP)** to **(AB)** for an already approved ANDA listed in the Orange Book. Any ANDA submission must contain an acceptable *in vivo* bioequivalence study for filing purposes.

1.4 REFERENCE LISTED DRUG

A reference listed drug (21 CFR 314.94(a)(3) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the reference listed may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes* of the *Introduction* to the *Approved Drug Products with Therapeutic Equivalence Evaluations* publication explains the coding system for multisource drug products listed under the same heading with two reference listed drugs.

The concept of having only one reference listed drug was intended to apply to drug products in which bioequivalence is demonstrated through *in vivo* methodology. It was not intended to apply to two NDA drug products in which the *in vivo* determination of bioequivalence is self evident and a waiver of *in vivo* bioequivalence is granted by the agency. These types of drug products are assigned therapeutic equivalence codes, e.g., of **AN**, **AT**, **AA**. Therefore, drug products that do not represent a bioequivalence problem with two or more NDAs will have the reference listed drug designation assigned to each NDA.

The reference listed drug is identified by the symbol " + " in the Prescription Drug Product List. These identified reference listed drugs represent the best judgement of the Division of Bioequivalence at this time. The prescription Drug Product List identifies reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, OFFICE OF GENERIC DRUGS, to confirm the appropriate reference listed drug.

1.5 COURT ORDER REGARDING ABBOTT U.S. PATENT NO. 4112097, (TERAZOSIN HCL)

On April 9, 1996, the United States District Court for the Northern District of Illinois (Eastern Division) issued an order in the case of Abbott Labs v. Geneva Pharmaceuticals, Inc., directing Abbott to remove U.S. Patent No. 4112097 from the Orange Book. To comply with that order, Abbott has requested that FDA remove patent 4112097 from the Orange Book. The FDA complied with this request in the March 1996 cumulative supplement. On April 9, 1996, Abbott appealed the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

1.6 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA is publishing a notice in the *Federal Register* advising NDA and NADA applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition that explains the background information on this court decision).

1.7 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs

[New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
1ST TEXAS PHARMACEUTICALS INC SUB SCHERER LABORATORIES (1ST TX)	SCHERER LABORATORIES, INC (SCHERER)
BARRE NATIONAL INC (BARRE)	ALPHARMA USPD INC (ALPHARMA)
BOEHRINGER MANNHEIM PHARMACEUTICALS CORP (BOEHRINGER MANNHEIM)	BOEHRINGER MANNHEIM CORPORATION THERAPEUTICS DIVISION (BOEHRINGER MANNHEIM)
DAVID BULL LABORATORIES PARTY LTD (BULL D)	FH FAULDING AND CO LTD (FAULDING) **THEN CHANGED TO** FAULDING PHARMACEUTICAL CO (FAULDING)
HOECHST ROUSSEL PHARMACEUTICALS INC (HOECHST ROUSSEL)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
KM LEE LABORORATORIES INC (KM LEE)	KM LEE LABORATORIES INC (LEE KM)
PHARMACIA INC (PHARMACIA)	PHARMACIA AND UPJOHN CO (PHARMACIA AND UPJOHN)
SCHWARZ PHARMA KREMERS URBAN CO SUB SCHWARZ PHARMA AG (SPKU)	SCHWARZ PHARMA INC (SCHWARZ PHARMA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
UPJOHN CO (UPJOHN)	PHARMACIA AND UPJOHN CO (PHARMACIA AND UPJOHN)
UPJOHN MANUFACTURING CO (UPJOHN)	PHARMACIA AND UPJOHN CARIBE INC (PHARMACIA AND UPJOHN)

1.8 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaces the Agency's electronic bulletin board and offers more information, in a more user-friendly form. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder/. You do not need an Internet connection to reach the CDER Home Page; you can use the free dial-up connection (800) 222-0185. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.9 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1995) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1995	MAR 1996	JUN 1996	SEP 1996
DRUG PRODUCTS LISTED	9286	9303	9384	9403
SINGLE SOURCE	2217 (23.9%)	2248 (24.2%)	2323 (24.8%)	2331 (24.8%)
MULTISOURCE	7069 (76.1%)	7055 (75.8%)	7061 (75.2%)	7072 (75.2%)
THERAPEUTICALLY EQUIVALENT	6437 (69.3%)	6425 (69.0%)	6490 (69.2%)	6519 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	440 (4.7%)	443 (4.8%)	468 (5.0%)	449 (4.8%)
EXCEPTIONS[1]	192 (2.1%)	187 (2.0%)	103 (1.0%)	104 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	6	15	14
NUMBER OF APPLICANTS	586	592	621	636

[1]Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

	BUTALBITAL AND ACETAMINOPHEN			
AB	HALSEY	**325MG;50MG**	**N89568 001**	
			OCT 05, 1988	
	@	325MG;50MG	N89568 001	
			OCT 05, 1988	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	ESGIC-PLUS			
	+ MIKART	500MG;50MG;40MG	N40085 001	
			MAR 28, 1996	

TABLET; ORAL

	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
	MIKART	**500MG;50MG;40MG**	**N89451 001**	
			MAY 23, 1988	
	+	500MG;50MG;40MG	N89451 001	
			MAY 23, 1988	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

	DHC PLUS			
AA	PURDUE FREDERICK	**356.4MG;30MG;16MG**	**N88584 001**	
			MAR 04, 1986	
	+	356.4MG;30MG;16MG	N88584 001	
			MAR 04, 1986	
	SYNALGOS-DC-A			
AA	+ WYETH AYERST	**356.4MG;30MG;16MG**	**N89166 001**	
			MAY 14, 1986	
	@	356.4MG;30MG;16MG	N89166 001	
			MAY 14, 1986	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	HI TECH PHARMA	**120MG/5ML;12MG/5ML**	**N40119 001**	
			APR 26, 1996	
>ADD> **AA**	MOVA	**120MG/5ML;12MG/5ML**	**N40098 001**	
>ADD>			SEP 20, 1996	
	TYLENOL W/ CODEINE			>ADD>
AA	JOHNSON RW	**120MG/5ML;12MG/5ML**	**N85057 001**	>ADD>

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

	TYLENOL W/ CODEINE			
AA	+ JOHNSON RW	**120MG/5ML;12MG/5ML**	**N85057 001**	

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	GENEVA PHARMS	**300MG;30MG**	**N85291 002**	
AA		**300MG;60MG**	**N85964 001**	
	@	300MG;30MG	N85291 002	
	@	300MG;60MG	N85964 001	
AA	HALSEY	**300MG;60MG**	**N86549 001**	
	@	300MG;60MG	N86549 001	
AA	MIKART	**300MG;30MG**	**N89238 001**	
			FEB 25, 1986	
AA		**300MG;60MG**	**N89244 001**	
			FEB 25, 1986	
	@	300MG;60MG	N89244 001	
			FEB 25, 1986	
	ACETAMINOPHEN AND CODEINE PHOSPHATE #3			
AA	MIKART	**300MG;30MG**	**N89238 001**	
			FEB 25, 1986	
AA	SUPERPHARM	**300MG;30MG**	**N89184 001**	
			OCT 18, 1985	
	@	300MG;30MG	N89184 001	
			OCT 18, 1985	
	ACETAMINOPHEN AND CODEINE PHOSPHATE #4			
AA	SUPERPHARM	**300MG;60MG**	**N89185 001**	
			OCT 18, 1985	
	@	300MG;60MG	N89185 001	
			OCT 18, 1985	
	ACETAMINOPHEN W/ CODEINE PHOSPHATE			
AA	HALSEY	**300MG;15MG**	**N83871 001**	
AA		**300MG;30MG**	**N83872 001**	
	@	300MG;15MG	N83871 001	
	@	300MG;30MG	N83872 001	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	ANEXSIA			
AA	KING PHARMS	**500MG;5MG**	**N89160 001**	
			APR 23, 1987	
AA	MALLINCKRODT	**500MG;5MG**	**N89160 001**	
			APR 23, 1987	
	ANEXSIA 10/660			>ADD>
AA	+ MALLINCKRODT	**660MG;10MG**	**N40084 003**	>ADD>
			JUL 29, 1996	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		ANEXSIA 10/660		
> DLT >		MALLINCKRODT	660MG;10MG	N40084 003
> DLT >				JUL 29, 1996
		ANEXSIA 7.5/650		
	AA	KING PHARMS	650MG;7.5MG	N89725 001
				SEP 30, 1987
	AA	MALLINCKRODT	650MG;7.5MG	N89725 001
				SEP 30, 1987
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
	AA	KING PHARMS	500MG;5MG	N40084 002
				JUN 01, 1995
	AA		750MG;7.5MG	N40084 001
				JUN 01, 1995
	AA	MALLINCKRODT	500MG;5MG	N40084 002
				JUN 01, 1995
	AA		750MG;7.5MG	N40084 001
				JUN 01, 1995
	AA	ROYCE LABS	500MG;2.5MG	N40123 003
				MAR 04, 1996
	AA		500MG;5MG	N40122 001
				MAR 04, 1996
	AA		500MG;7.5MG	N40123 004
				MAR 04, 1996
	AA		650MG;7.5MG	N40123 001
				MAR 04, 1996
	AA		650MG;10MG	N40123 002
				MAR 04, 1996
	AA		750MG;7.5MG	N40122 002
				MAR 04, 1996
	AA	VINTAGE PHARMS	500MG;7.5MG	N40144 001
				FEB 22, 1996
	AA		650MG;10MG	N40143 001
				FEB 22, 1996
	AA		750MG;7.5MG	N40157 001
				APR 12, 1996
		LORTAB		
		+ GRAHAM	500MG;10MG	N40100 001
				JAN 26, 1996
		+ UCB	500MG;10MG	N40100 001
				JAN 26, 1996
> ADD >		**VICODIN HP**		
> ADD >	AA	KNOLL PHARM	660MG;10MG	N40117 001
> ADD >				SEP 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

		OXYCODONE AND ACETAMINOPHEN		
AA		VINTAGE PHARMS	500MG;5MG	N40106 001
				JUL 30, 1996

TABLET; ORAL

		OXYCODONE AND ACETAMINOPHEN		
AA		VINTAGE PHARMS	325MG;5MG	N40105 001
				JUL 30, 1996

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN		
AB		SUPERPHARM	650MG;100MG	N71319 001
				JAN 06, 1987
	@		650MG;100MG	N71319 001
				JAN 06, 1987

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

		ACETIC ACID		
AT		MORTON GROVE	2%	N40166 001
				JUL 26, 1996

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

		HYDROCORTISONE AND ACETIC ACID		
AT		MORTON GROVE	2%;1%	N40168 001
				AUG 30, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

		SEMPREX-D		
	+	GLAXO WELLCOME	8MG;60MG	N19806 001
				MAR 25, 1994
	+	MEDEVA AMERICAS	8MG;60MG	N19806 001
				MAR 25, 1994

ADAPALENE

GEL; TOPICAL
DIFFERIN
+ GALDERMA 0.1% N20380 001 MAY 31, 1996

SOLUTION; TOPICAL
DIFFERIN
+ GALDERMA 0.1% N20338 001 MAY 31, 1996

ALBENDAZOLE

TABLET; ORAL
ALBENZA
+ SMITHKLINE BEECHAM 200MG N20666 001 JUN 11, 1996

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB ARMSTRONG PHARMS **0.09MG/INH** **N72273 001** AUG 14, 1996
AB MEDISOL **0.09MG/INH** **N74072 001** AUG 01, 1996

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA
+ 3M EQ 0.09MG BASE/INH N20503 001 AUG 15, 1996

SOLUTION; INHALATION
VENTOLIN
AN GLAXO WELLCOME **EQ 0.083% BASE** **N19773 001** APR 23, 1992
AN + **EQ 0.083% BASE** **N19773 001** APR 23, 1992
AN **EQ 0.5% BASE** **N19269 002** JAN 16, 1987
AN + **EQ 0.5% BASE** **N19269 002** JAN 16, 1987

ALBUTEROL SULFATE

SYRUP; ORAL
PROVENTIL
AA SCHERING **EQ 2MG BASE/5ML** **N18062 001** JAN 19, 1983
AA + **EQ 2MG BASE/5ML** **N18062 001** JAN 19, 1983

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ZYLOPRIM
+ GLAXO WELLCOME EQ 500MG BASE/VIAL N20298 001 MAY 17, 1996

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
AB NOVOPHARM **2MG** **N74085 004** FEB 26, 1996

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
PHARMACIA AND UPJOHN 0.005MG/VIAL N20379 003 JUN 27, 1996

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN-HF 8%
ABBOTT 8% N20345 001 APR 04, 1996

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
CLINTEC NUTR 15% N20512 001 AUG 30, 1996

HEPATASOL 8%
BAXTER 8% N20360 001 APR 04, 1996

AMINOPHYLLINE

TABLET; ORAL

	AMINOPHYLLINE			
	@ PHOENIX LABS NY	100MG		N85409 001
	@	200MG		N85410 001
	@ VINTAGE PHARMS	100MG		N85409 001
	@	200MG		N85410 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIPTYLINE HCL			
BP	HALSEY	25MG		N85922 001
	@	25MG		N85922 001
	ENDEP			
AB	ROCHE	**150MG**		**N85303 001**
	@	150MG		N85303 001

AMMONIUM LACTATE

CREAM; TOPICAL

	LAC-HYDRIN			
	BRISTOL MYERS	EQ 12% BASE		N20508 001 AUG 29, 1996

AMOXICILLIN

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	APOTHECON	**125MG**		**N64131 001** MAY 06, 1996
AB		**250MG**		**N64131 002** MAY 06, 1996
AB	CLONMEL HLTH CARE	**125MG**		**N64139 001** JAN 29, 1996
AB		**250MG**		**N64139 002** JAN 29, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	AUGMENTIN '200'			
+	SMITHKLINE BEECHAM	200MG/5ML; EQ 28.5MG BASE/5ML		N50725 001 MAY 31, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	AUGMENTIN '400'			
+	SMITHKLINE BEECHAM	400MG/5ML; EQ 57MG BASE/5ML		N50725 002 MAY 31, 1996

TABLET; ORAL

	AUGMENTIN '875'			
+	SMITHKLINE BEECHAM	875MG;EQ 125MG BASE		N50720 001 FEB 13, 1996

TABLET, CHEWABLE; ORAL

	AUGMENTIN '200'			
+	SMITHKLINE BEECHAM	200MG;EQ 28.5MG BASE		N50726 001 MAY 31, 1996
	AUGMENTIN '400'			
+	SMITHKLINE BEECHAM	400MG;EQ 57MG BASE		N50726 002 MAY 31, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	ADDERALL 10			
	RICHWOOD PHARM	2.5MG;2.5MG;2.5MG;2.5MG		N11522 007 FEB 13, 1996
	ADDERALL 20			
+	RICHWOOD PHARM	5MG;5MG;5MG;5MG		N11522 008 FEB 13, 1996

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	BIPHETAMINE 12.5			
	@ FISONS	EQ 6.25MG BASE; EQ 6.25MG BASE		N10093 007
	@ MEDEVA PHARMS	EQ 6.25MG BASE; EQ 6.25MG BASE		N10093 007
	BIPHETAMINE 20			
	@ FISONS	EQ 10MG BASE;EQ 10MG BASE		N10093 003
	@ MEDEVA PHARMS	EQ 10MG BASE;EQ 10MG BASE		N10093 003
	BIPHETAMINE 7.5			
	@ FISONS	EQ 3.75MG BASE; EQ 3.75MG BASE		N10093 009

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

		BIPHETAMINE 7.5		
		@ MEDEVA PHARMS	EQ 3.75MG BASE; EQ 3.75MG BASE	N10093 009

AMPHOTERICIN B

SUSPENSION; ORAL

		FUNGIZONE		
	+	BRISTOL MYERS SQUIBB	100MG/ML	N50341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

		OMNIPEN-N		
> DLT >	AP	WYETH AYERST	EQ 2GM BASE/VIAL	N60626 005
> ADD >	AP	+	EQ 2GM BASE/VIAL	N60626 005
> DLT >		PENBRITIN-S		
> DLT >	AP	WYETH AYERST	EQ 125MG BASE/VIAL	N50072 001
> DLT >	AP		EQ 250MG BASE/VIAL	N50072 002
> DLT >	AP		EQ 500MG BASE/VIAL	N50072 003
> DLT >	AP		EQ 1GM BASE/VIAL	N50072 004
> DLT >	AP		EQ 2GM BASE/VIAL	N50072 005
> DLT >	AP	+	EQ 125MG BASE/VIAL	N50072 001
> ADD >		@	EQ 250MG BASE/VIAL	N50072 002
> ADD >		@	EQ 500MG BASE/VIAL	N50072 003
> ADD >		@	EQ 1GM BASE/VIAL	N50072 004
> ADD >		@	EQ 2GM BASE/VIAL	N50072 005

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

> DLT >		PFIZERPEN-A		
> DLT >	AB	PFIZER	EQ 250MG BASE	N62050 001
> DLT >	AB		EQ 500MG BASE	N62050 002
> ADD >		@	EQ 250MG BASE	N62050 001
> ADD >		@	EQ 500MG BASE	N62050 002

POWDER FOR RECONSTITUTION; ORAL

> DLT >		PFIZERPEN-A		
> DLT >	AB	PFIZER	EQ 125MG BASE/5ML	N62049 001
> DLT >	AB		EQ 250MG BASE/5ML	N62049 002
> ADD >		@	EQ 125MG BASE/5ML	N62049 001
> ADD >		@	EQ 250MG BASE/5ML	N62049 002

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

		POLYCILLIN-PRB		
AB	+	APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	N61898 001
		@	EQ 3.5GM BASE/BOT;1GM/BOT	N61898 001
		PROBAMPACIN		
AB		BIOCRAFT	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001
	+	@	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

		BUTALBITAL, ASPIRIN & CAFFEINE		
AB		HALSEY	325MG;50MG;40MG	N89448 001 DEC 01, 1986
		@	325MG;50MG;40MG	N89448 001 DEC 01, 1986

ASPIRIN; CARISOPRODOL

TABLET; ORAL

		CARISOPRODOL AND ASPIRIN		
AB		EON LABS	325MG;200MG	N40116 001 APR 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

		CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE		
AB		EON LABS	325MG;200MG;16MG	N40118 001 APR 16, 1996
		SOMA COMPOUND W/ CODEINE		
AB	+	WALLACE PHARMS	325MG;200MG;16MG	N12366 002 JUL 11, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

		LOGEN		
AA		SUPERPHARM	0.025MG;2.5MG	N88962 001 MAY 10, 1985
		@	0.025MG;2.5MG	N88962 001 MAY 10, 1985
		LOW-QUEL		
AA		HALSEY	0.025MG;2.5MG	N85211 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
LOW-QUEL
@ HALSEY 0.025MG;2.5MG N85211 001

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE
AB ROXANE **50MG** **N74069 001** FEB 16, 1996

IMURAN
AB + GLAXO WELLCOME **50MG** **N16324 001**

AZITHROMYCIN DIHYDRATE

TABLET; ORAL
ZITHROMAX
+ PFIZER EQ 250MG BASE N50711 001 JUL 18, 1996
+ EQ 600MG BASE N50730 001 JUN 12, 1996

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN
AT ALTANA **500 UNITS/GM** **N61212 001**
+ 500 UNITS/GM N61212 001
AT + LILLY **500 UNITS/GM** **N60687 001**
@ 500 UNITS/GM N60687 001

BACLOFEN

TABLET; ORAL
BACLOFEN
AB CHELSEA LABS **10MG** **N74698 001** AUG 20, 1996
AB **20MG** **N74698 002** AUG 20, 1996
AB ROSEMONT **10MG** **N74584 001** AUG 19, 1996
AB **20MG** **N74584 002** AUG 19, 1996

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ
BN + GLAXO WELLCOME EQ 0.042MG DIPROP/INH N19389 001 JUL 27, 1987
BN EQ 0.042MG DIPROP/INH N19389 001 JUL 27, 1987

VANCENASE AQ
BN SCHERING EQ 0.042MG DIPROP/INH N19589 001 DEC 23, 1987
BN + EQ 0.042MG DIPROP/INH N19589 001 DEC 23, 1987
+ EQ 0.084MG DIPROP/INH N20469 001 JUN 26, 1996

BETA-CAROTENE

> DLT >
> DLT >
> DLT >
> ADD >

CAPSULE; ORAL
SOLATENE
+ ROCHE 30MG N17589 001
@ 30MG N17589 001

BETAMETHASONE BENZOATE

> DLT >
> DLT >
> DLT >
> ADD >

CREAM; TOPICAL
UTICORT
+ PARKE DAVIS 0.025% N16998 002
@ 0.025% N16998 002

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC
+ PROCTER AND GAMBLE 262.4MG;250MG;500MG N50719 001 AUG 15, 1996

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLENOXANE
AP + BRISTOL MYERS SQUIBB **EQ 15 UNITS BASE/VIAL** N50443 001
+ EQ 15 UNITS BASE/VIAL N50443 001

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP		PHARMACIA AND UPJOHN	EQ 15 UNITS BASE/VIAL	N64084 001 JUN 01, 1996
	+		EQ 30 UNITS BASE/VIAL	N64084 002 JUN 01, 1996

> ADD > BRIMONIDINE TARTRATE

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > ALPHAGAN
> ADD > + ALLERGAN 0.2% N20613 001
> ADD > SEP 06, 1996

BROMPHENIRAMINE MALEATE

TABLET; ORAL
DIMETANE

AA	+	ROBINS AH	4MG	N10799 003
	@	WHITEHALL ROBINS	4MG	N10799 003

BUCLIZINE HYDROCHLORIDE

> DLT > TABLET; ORAL
> DLT > BUCLADIN-S
> DLT > STUART 50MG N10911 006
> ADD > @ 50MG N10911 006

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENEX

AP	+	RECKITT AND COLMAN	EQ 0.3MG BASE/ML	N18401 001

BUPRENORPHINE HCL

AP		SANOFI WINTHROP	EQ 0.3MG BASE/ML	N74137 001 JUN 03, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR
+ BRISTOL MYERS SQUIBB 10MG N18731 002
SEP 29, 1986

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR

		BRISTOL MYERS SQUIBB	10MG	N18731 002 SEP 29, 1986
	+		15MG	N18731 003 APR 22, 1996
	@		30MG	N18731 004 APR 22, 1996

BUTABARBITAL SODIUM

ELIXIR; ORAL
SARISOL

AA		HALSEY	30MG/5ML	N84723 001
	@		30MG/5ML	N84723 001

TABLET; ORAL
SARISOL NO. 1

AA		HALSEY	15MG	N84719 001
	@		15MG	N84719 001

SARISOL NO. 2

AA		HALSEY	30MG	N84719 002
	@		30MG	N84719 002

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005% N20554 001
JUL 22, 1996

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

	DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER		
AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 002
	DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER		
AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 003

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 007 JUN 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 001

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 004 JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 005 JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 008 JUN 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 006 JUL 07, 1982

INPERSOL W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 002

INPERSOL W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 003

INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 007 JUN 24, 1988

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 001

INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 004 JUL 07, 1982

INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 005 JUL 07, 1982

INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 008 JUN 24, 1988

INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 006 JUL 07, 1982

> ADD > CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

> ADD > INJECTABLE; INTRATHECAL

> ADD > ELLIOTTS B SOLUTION

> ADD > +	ORPHAN MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML; 1.9MG/ML;7.3MG/ML;	
> ADD >		0.2MG/ML	N20577 001 SEP 27, 1996

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB	BRISTOL MYERS SQUIBB	100MG	N18343 003
AB +		100MG	N18343 003

CAPTOPRIL

TABLET; ORAL

	CAPOTEN			
	BRISTOL MYERS SQUIBB	75MG	N18343 007	JUN 13, 1995
*		150MG	N18343 004	JUN 13, 1995
@		75MG	N18343 007	JUN 13, 1995
@		150MG	N18343 004	JUN 13, 1995
	CAPTOPRIL			
AB	BAKER NORTON	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996
AB	BIOCRAFT	12.5MG	N74433 001	FEB 13, 1996
AB		25MG	N74433 002	FEB 13, 1996
AB		50MG	N74433 003	FEB 13, 1996
AB		100MG	N74433 004	FEB 13, 1996
AB	CHELSEA LABS	12.5MG	N74576 001	APR 23, 1996
AB		25MG	N74576 002	APR 23, 1996
AB		50MG	N74576 003	APR 23, 1996
AB		100MG	N74576 004	APR 23, 1996
AB	COPLEY PHARM	12.5MG	N74462 001	FEB 13, 1996
AB		25MG	N74462 002	FEB 13, 1996
AB		50MG	N74462 003	FEB 13, 1996
AB		100MG	N74462 004	FEB 13, 1996
AB	DANBURY PHARMA	12.5MG	N74386 001	MAY 23, 1996
AB		25MG	N74386 002	MAY 23, 1996

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL			
AB	DANBURY PHARMA	50MG	N74386 003	MAY 23, 1996
AB		100MG	N74386 004	MAY 23, 1996
AB	ENDO LABS	12.5MG	N74418 001	FEB 13, 1996
AB		25MG	N74418 002	FEB 13, 1996
AB		50MG	N74418 003	FEB 13, 1996
AB		100MG	N74418 004	FEB 13, 1996
AB	EON LABS	12.5MG	N74519 001	FEB 13, 1996
AB		25MG	N74519 002	FEB 13, 1996
AB		50MG	N74519 003	FEB 13, 1996
AB		100MG	N74519 004	FEB 13, 1996
AB	HALLMARK PHARMS	12.5MG	N74477 001	FEB 13, 1996
AB		25MG	N74477 002	FEB 13, 1996
AB		50MG	N74477 003	FEB 13, 1996
AB		100MG	N74477 004	FEB 13, 1996
AB	INVAMED	12.5MG	N74481 001	FEB 13, 1996
AB		25MG	N74481 002	FEB 13, 1996
AB		50MG	N74481 003	FEB 13, 1996
AB		100MG	N74481 004	FEB 13, 1996
AB	LEMMON	12.5MG	N74483 001	FEB 13, 1996
AB		25MG	N74483 002	FEB 13, 1996
AB		50MG	N74483 003	FEB 13, 1996
AB		100MG	N74483 004	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	MOVA	12.5MG	N74423 001		FEB 13, 1996
AB		25MG	N74423 002		FEB 13, 1996
AB		50MG	N74423 003		FEB 13, 1996
AB		100MG	N74423 004		FEB 13, 1996
AB	MYLAN	12.5MG	N74434 001		FEB 13, 1996
AB		25MG	N74434 002		FEB 13, 1996
AB		50MG	N74434 003		FEB 13, 1996
AB		100MG	N74434 004		FEB 13, 1996
AB	NOVOPHARM	12.5MG	N74322 001		FEB 13, 1996
AB		25MG	N74322 002		FEB 13, 1996
AB		50MG	N74322 003		FEB 13, 1996
AB		100MG	N74322 004		FEB 13, 1996
AB	PAR PHARM	12.5MG	N74493 001		FEB 13, 1996
AB		25MG	N74493 002		FEB 13, 1996
AB		50MG	N74493 003	> ADD >	FEB 13, 1996 > ADD >
AB		100MG	N74493 004	> ADD >	FEB 13, 1996 > ADD >
AB	ROYCE LABS	12.5MG	N74451 001		FEB 13, 1996
AB		25MG	N74451 002		FEB 13, 1996
AB		50MG	N74451 003		FEB 13, 1996
AB		100MG	N74451 004	> ADD >	FEB 13, 1996 > ADD >
AB	WEST WARD	12.5MG	N74505 001	> ADD >	FEB 13, 1996 > ADD >
AB		25MG	N74505 002		FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	WEST WARD	50MG	N74505 003 FEB 13, 1996
AB		100MG	N74505 004 FEB 13, 1996

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR

+	CIBA GEIGY	100MG	N20234 001 MAR 25, 1996
+		200MG	N20234 002 MAR 25, 1996
+		400MG	N20234 003 MAR 25, 1996

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	WEST WARD	350MG	N40124 001 JAN 24, 1996

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

+	GUILFORD PHARMS	7.7MG	N20637 001 SEP 23, 1996

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB	BIOCRAFT	EQ 250MG BASE	N64081 001 SEP 16, 1996
AB		EQ 500MG BASE	N64081 002 SEP 16, 1996
AB	MARSAM	EQ 250MG BASE	N64148 001 MAY 23, 1996

CEFACLOR

CAPSULE; ORAL

	CEFACLOR			
AB	MARSAM	**EQ 500MG BASE**	**N64148 002**	
			MAY 23, 1996	
AB	NOVOPHARM	**EQ 250MG BASE**	**N64145 001**	
			JUN 24, 1996	
AB		**EQ 500MG BASE**	**N64145 002**	
			JUN 24, 1996	

TABLET, EXTENDED RELEASE; ORAL

	CECLOR CD			
+	LILLY	EQ 375MG BASE	N50673 001	
			JUN 28, 1996	
+		EQ 500MG BASE	N50673 002	
			JUN 28, 1996	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER			
+	BAXTER	EQ 10MG BASE/ML	N50566 003	
			JUN 08, 1983	
+		EQ 20MG BASE/ML	N50566 004	
			JUN 08, 1983	
@		EQ 10MG BASE/ML	N50566 003	
			JUN 08, 1983	
@		EQ 20MG BASE/ML	N50566 004	
			JUN 08, 1983	

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION

	MAXIPIME			
+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N50679 001	
			JAN 18, 1996	
+		EQ 1GM BASE/VIAL	N50679 002	
			JAN 18, 1996	
+		EQ 2GM BASE/VIAL	N50679 003	
			JAN 18, 1996	

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
+	GLAXO WELLCOME	500MG/VIAL	N50646 001	
			SEP 27, 1990	
@		500MG/VIAL	N50646 001	
			SEP 27, 1990	

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

	CEFTAZIDIME SODIUM IN PLASTIC CONTAINER			
AP	BAXTER	**EQ 10MG BASE/ML**	**N63221 001**	
			APR 29, 1993	
+		EQ 10MG BASE/ML	N63221 001	
			APR 29, 1993	
	FORTAZ IN PLASTIC CONTAINER			
AP	+ GLAXO WELLCOME	**EQ 10MG BASE/ML**	**N50634 001**	
			APR 28, 1989	
@		EQ 10MG BASE/ML	N50634 001	
			APR 28, 1989	

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

	ROCEPHIN			
	ROCHE	EQ 500MG BASE/VIAL	N62654 001	
			APR 30, 1987	
@		EQ 500MG BASE/VIAL	N62654 001	
			APR 30, 1987	

CEPHALEXIN

CAPSULE; ORAL

	CEFANEX			
AB	APOTHECON	**EQ 250MG BASE**	**N63063 001**	
			SEP 29, 1989	
AB		**EQ 500MG BASE**	**N63063 002**	
			SEP 29, 1989	
	CEPHALEXIN			
AB	APOTHECON	**EQ 250MG BASE**	**N63063 001**	
			SEP 29, 1989	
AB		**EQ 500MG BASE**	**N63063 002**	
			SEP 29, 1989	

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	YOSHITOMI	EQ 250MG BASE	N62872 001 JUN 20, 1988	
AB		EQ 500MG BASE	N62871 001 JUL 05, 1988	
@		EQ 250MG BASE	N62872 001 JUN 20, 1988	
@		EQ 500MG BASE	N62871 001 JUL 05, 1988	>ADD>

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

+	BAXTER	EQ 20MG BASE/ML	N62422 003 JAN 31, 1984	
		EQ 20MG BASE/ML	N62422 005 JUL 16, 1991	
		EQ 20MG BASE/ML	N62730 001 MAR 05, 1987	
+		EQ 40MG BASE/ML	N62422 004 JAN 31, 1984	
		EQ 40MG BASE/ML	N62422 006 JUL 16, 1991	
		EQ 40MG BASE/ML	N62730 002 MAR 05, 1987	
@		EQ 20MG BASE/ML	N62422 003 JAN 31, 1984	
@		EQ 20MG BASE/ML	N62422 005 JUL 16, 1991	
@		EQ 20MG BASE/ML	N62730 001 MAR 05, 1987	
@		EQ 40MG BASE/ML	N62422 004 JAN 31, 1984	
@		EQ 40MG BASE/ML	N62422 006 JUL 16, 1991	
@		EQ 40MG BASE/ML	N62730 002 MAR 05, 1987	

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

+	BAXTER	EQ 20MG BASE/ML	N62422 001 JAN 31, 1984	
+		EQ 40MG BASE/ML	N62422 002 JAN 31, 1984	
@		EQ 20MG BASE/ML	N62422 001 JAN 31, 1984	

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

@	BAXTER	EQ 40MG BASE/ML	N62422 002 JAN 31, 1984	

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
ZYRTEC

+	PFIZER	5MG/5ML	N20346 001 SEP 27, 1996	>ADD>

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

AB	HALSEY	5MG	N85340 001	
AB		10MG	N85339 001	
AB		25MG	N84685 001	
@		5MG	N85340 001	
@		10MG	N85339 001	
@		25MG	N84685 001	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	0.12%	N74356 001 MAY 07, 1996	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLOR-TRIMETON

AP	+ SCHERING PLOUGH	10MG/ML	N08826 001	
@		10MG/ML	N08826 001	

CHLORPHENIRAMINE MALEATE

AP	STERIS	10MG/ML	N86096 001	
+		10MG/ML	N86096 001	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

	TUSSIONEX			
+	FISONS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001 DEC 31, 1987	
+	MEDEVA PHARMS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001 DEC 31, 1987	

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
AB	BARR	100MG	N88812 001 OCT 19, 1984	
AB		100MG	N89446 001 NOV 17, 1986	
AB		250MG	N88813 001 OCT 19, 1984	
AB		250MG	N89447 001 NOV 17, 1986	
@		100MG	N88812 001 OCT 19, 1984	
@		100MG	N89446 001 NOV 17, 1986	
@		250MG	N88813 001 OCT 19, 1984	
@		250MG	N89447 001 NOV 17, 1986	
AB	HALSEY	100MG	N89321 001 JAN 16, 1986	
AB		250MG	N88662 001 JAN 09, 1986	
@		100MG	N89321 001 JAN 16, 1986	
@		250MG	N88662 001 JAN 09, 1986	
AB	SUPERPHARM	250MG	N88695 001 SEP 17, 1984	
@		250MG	N88695 001 SEP 17, 1984	

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	SUPERPHARM	50MG	N87247 001 FEB 09, 1983	
@		50MG	N87247 001 FEB 09, 1983	

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	CHELSEA LABS	500MG	N40137 001 AUG 09, 1996	

CHOLESTYRAMINE

POWDER; ORAL

	LOCHOLEST			
AB	EON LABS	EQ 4GM RESIN/PACKET	N74557 001 AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74557 002 AUG 15, 1996	
AB		EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002 AUG 15, 1996	
	LOCHOLEST LIGHT			
AB	EON LABS	EQ 4GM RESIN/PACKET	N74558 001 AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74558 002 AUG 15, 1996	
AB		EQ 4GM RESIN/PACKET	N74562 001 AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002 AUG 15, 1996	
	PREVALITE			
AB	UPSHER SMITH	EQ 4GM RESIN/PACKET	N73263 001 FEB 22, 1996	
	QUESTRAN			
AB	+ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N16640 001	
AB		EQ 4GM RESIN/SCOOPFUL	N16640 003	
	QUESTRAN LIGHT			
AB	+ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N19669 001 DEC 05, 1988	

CHOLESTYRAMINE

POWDER; ORAL
QUESTRAN LIGHT

AB	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N19669 001 DEC 05, 1988	
AB		EQ 4GM RESIN/SCOOPFUL	N19669 003 DEC 05, 1988	

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE

AP	FUJISAWA	EQ 0.004MG CHROMIUM/ML	N19271 001 MAY 05, 1987	
	@	EQ 0.004MG CHROMIUM/ML	N19271 001 MAY 05, 1987	

CHROMIC CHLORIDE IN PLASTIC CONTAINER

AP	+ ABBOTT	EQ 0.004MG CHROMIUM/ML	N18961 001 JUN 26, 1986	> ADD > > ADD >
	+	EQ 0.004MG CHROMIUM/ML	N18961 001 JUN 26, 1986	> DLT > > ADD >

CIDOFOVIR

INJECTABLE; INJECTION
VISTIDE

+	GILEAD	EQ 75MG BASE/ML	N20638 001 JUN 26, 1996

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	DANBURY PHARMA	200MG	N74349 001 AUG 30, 1996	> ADD > > ADD >
AB		300MG	N74349 002 AUG 30, 1996	> ADD >
AB		400MG	N74349 003 AUG 30, 1996	
AB		800MG	N74316 001 FEB 28, 1996	> ADD > > ADD >
AB	INVAMED	200MG	N74506 001 JAN 24, 1996	> ADD > > ADD >
AB		300MG	N74506 002 JAN 24, 1996	> ADD >

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	INVAMED	400MG	N74506 003 JAN 24, 1996
AB		800MG	N74506 004 JAN 24, 1996

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	MOVA	EQ 300MG BASE/2ML	N74428 001 APR 25, 1996

SOLUTION; ORAL
CIMETIDINE HCL

AA	LEMMON	EQ 300MG BASE/5ML	N74610 001 SEP 26, 1996	

TAGAMET

AA	SMITHKLINE BEECHAM	EQ 300MG BASE/5ML	N17924 001	> DLT > > ADD >
AA	+	EQ 300MG BASE/5ML	N17924 001	

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPRO

	BAYER	EQ 100MG BASE	N19537 001 APR 08, 1996

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	STIEFEL	EQ 1% BASE	N64108 001 SEP 27, 1996	> ADD > > ADD >

SWAB; TOPICAL
CLEOCIN

AT	PHARMACIA AND UPJOHN	EQ 1% BASE	N50537 002 FEB 22, 1994	> ADD > > ADD >

CLINDETS

AT	STIEFEL	EQ 1% BASE	N64136 001 SEP 30, 1996	> ADD > > ADD >

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

> ADD >	AB	FOUGERA	0.05%	N74392 001	
> ADD >				SEP 30, 1996	
	AB	TARO	0.05%	N74249 001	
				JUL 08, 1996	

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA	0.05%	N74407 001	
			FEB 23, 1996	
AB	TARO	0.05%	N74248 001	
			JUL 12, 1996	

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	CIBA GEIGY	25MG	N19906 001	
			DEC 29, 1989	
AB +		50MG	N19906 002	
			DEC 29, 1989	
AB		75MG	N19906 003	
			DEC 29, 1989	

CLOMIPRAMINE HCL

AB	GENEVA PHARMS	25MG	N74364 001	
			MAR 29, 1996	
AB		50MG	N74364 002	
			MAR 29, 1996	
AB		75MG	N74364 003	
			MAR 29, 1996	

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

> ADD >					
> ADD >	AB	LEMMON	0.5MG	N74569 001	
> ADD >				SEP 10, 1996	
> ADD >	AB		1MG	N74569 002	
> ADD >				SEP 10, 1996	
> ADD >	AB		2MG	N74569 003	
> ADD >				SEP 10, 1996	

KLONOPIN

> ADD >	AB	ROCHE	0.5MG	N17533 001	
> ADD >	AB		1MG	N17533 002	

CLONAZEPAM

TABLET; ORAL

KLONOPIN

> ADD >	AB +	ROCHE	2MG	N17533 003	

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT	TARO	1%	N74580 001	
			JUL 29, 1996	

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB	CREIGHTON	25MG	N74546 001	
			AUG 30, 1996	
AB		100MG	N74546 002	
			AUG 30, 1996	

CLOZARIL

AB +	SANDOZ	25MG	N19758 001	
			SEP 26, 1989	
AB		100MG	N19758 002	
			SEP 26, 1989	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE VC W/ CODEINE

AA	HALSEY	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88870 001	
			MAR 02, 1987	
@		10MG/5ML;5MG/5ML; 6.25MG/5ML	N88870 001	
			MAR 02, 1987	

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

+	FERRING LABS	EQ 0.1MG BASE/VIAL	N20162 001	
			MAY 23, 1996	

CROMOLYN SODIUM

CAPSULE; ORAL
GASTROCROM

	+	FISONS	100MG	N19188 001 DEC 22, 1989
	+	MEDEVA PHARMS	100MG	N19188 001 DEC 22, 1989

CONCENTRATE; ORAL
GASTROCROM

	+	FISONS	100MG/5ML	N20479 001 FEB 29, 1996
	+	MEDEVA PHARMS	100MG/5ML	N20479 001 FEB 29, 1996

CYANOCOBALAMIN

INJECTABLE; INJECTION

		BETALIN 12		
AP		LILLY	**0.1MG/ML**	**N80855 001**
AP			**1MG/ML**	**N80855 002**
	@		0.1MG/ML	N80855 001
	@		1MG/ML	N80855 002
		CYANOCOBALAMIN		
>DLT> **AP**		DELL LABS	**0.1MG/ML**	**N80689 002**
>DLT> **AP**			**1MG/ML**	**N80689 003**
>DLT>			0.03MG/ML	N80689 001
>ADD>	@		0.03MG/ML	N80689 001
>ADD>	@		0.1MG/ML	N80689 002
>ADD>	@		1MG/ML	N80689 003

CYCLOTHIAZIDE

TABLET; ORAL
ANHYDRON

	+	LILLY	2MG	N13157 002
	@		2MG	N13157 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL

AA		HALSEY	**2MG/5ML**	**N89199 001** JUL 03, 1986

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL

	@	HALSEY	2MG/5ML	N89199 001 JUL 03, 1986

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN

	+	PHARMACIA AND UPJOHN	5,000 IU/0.2ML	N20287 003 MAR 18, 1996

DANAZOL

CAPSULE; ORAL
DANAZOL

AB		BARR	**200MG**	**N74582 001** AUG 09, 1996
		DANOCRINE		
AB	+	SANOFI WINTHROP	**200MG**	**N17557 002**

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

	+	NEXSTAR	EQ 2MG BASE/ML	N50704 002 APR 08, 1996

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL

AB		EON LABS	**10MG**	**N74430 001** FEB 09, 1996
AB			**150MG**	**N74430 002** FEB 09, 1996

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE

>DLT>	+	ARMOUR PHARM	0.15MG/INH	N20355 001 MAR 07, 1994
>DLT>				

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

		STIMATE			
> ADD >	+	CENTEON	0.15MG/INH	N20355 001	
> ADD >				MAR 07, 1994	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

		ORTHO-CEPT			
		JOHNSON RW	0.15MG;0.03MG	N20301 001	
				DEC 14, 1992	
	+		0.15MG;0.03MG	N20301 001	
				DEC 14, 1992	

DESOXIMETASONE

OINTMENT; TOPICAL

		DESOXIMETASONE			
AB		TARO	0.25%	**N74286 001**	
				JUN 07, 1996	
		TOPICORT			
AB	+	HOECHST MARION RSSL	0.25%	**N18763 001**	
				SEP 30, 1983	

DEXAMETHASONE

CONCENTRATE; ORAL

		DEXAMETHASONE INTENSOL			
		ROXANE	1MG/ML	N88252 001	
				SEP 01, 1983	

SOLUTION; ORAL

		DEXAMETHASONE INTENSOL			
		ROXANE	0.5MG/0.5ML	N88252 001	
				SEP 01, 1983	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		DEXACIDIN			
AT		CIBA	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	**N62566 001**	
				FEB 22, 1985	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		DEXACIDIN			
AT		IOLAB	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	**N62566 001**	
				FEB 22, 1985	

SUSPENSION/DROPS; OPHTHALMIC

		DEXACIDIN			
AT		CIBA	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N62544 001**	
				OCT 29, 1984	
AT		IOLAB	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N62544 001**	
				OCT 29, 1984	

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

		DEXAMETHASONE SODIUM PHOSPHATE			
AT		BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	**N40069 001**	
				JUL 26, 1996	

DEXFENFLURAMINE HYDROCHLORIDE

CAPSULE; ORAL

		REDUX			
	+	INTERNEURON	15MG	N20344 001	
				APR 29, 1996	

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

		DEXTROAMPHETAMINE SULFATE			
AA		HALSEY	10MG	**N83930 001**	
	@		10MG	N83930 001	
AA		MM MAST	5MG	**N86521 001**	
	@		5MG	N86521 001	
AA	+	REXAR	10MG	**N84051 002**	
	+		10MG	N84051 002	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHERAZINE DM			
AA	HALSEY	15MG/5ML;6.25MG/5ML	N88913 001	MAR 02, 1987
@		15MG/5ML;6.25MG/5ML	N88913 001	MAR 02, 1987
	PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE			
AA	HI TECH PHARMA	15MG/5ML;6.25MG/5ML	N40027 001	JUL 31, 1996

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
MCGAW	10GM/100ML;200MG/100ML	N18386 001	
@	10GM/100ML;200MG/100ML	N18386 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
MCGAW	10GM/100ML;450MG/100ML	N18229 001	
@	10GM/100ML;450MG/100ML	N18229 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
MCGAW	2.5GM/100ML;900MG/100ML	N18376 001	
@	2.5GM/100ML;900MG/100ML	N18376 001	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	MD-76			
AP	MALLINCKRODT	66%;10%	N19292 001	SEP 29, 1989
	MD-76R			
AP	MALLINCKRODT	66%;10%	N19292 001	SEP 29, 1989

DIATRIZOATE SODIUM

SOLUTION; URETERAL

	HYPAQUE SODIUM 20%			
AT	NYCOMED	20%	N09561 002	
		20%	N09561 002	

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	NOVOPHARM	75MG	N74390 001	AUG 15, 1996
AB	PUREPAC PHARM	50MG	N74514 001	MAR 26, 1996
AB		75MG	N74514 002	MAR 26, 1996

TABLET, EXTENDED RELEASE; ORAL

	VOLTAREN-XR			
+	GEIGY	100MG	N20254 001	MAR 08, 1996

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	EQ 250MG BASE	N61454 001	
AB +		EQ 250MG BASE	N61454 001	
AB		EQ 500MG BASE	N61454 003	
AB +		EQ 500MG BASE	N61454 003	
	PATHOCIL			
AB +	WYETH AYERST	EQ 250MG BASE	N50011 002	
AB		EQ 250MG BASE	N50011 002	
AB +		EQ 500MG BASE	N50011 003	MAR 28, 1983
AB		EQ 500MG BASE	N50011 003	MAR 28, 1983

POWDER FOR RECONSTITUTION; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	
AB +		EQ 62.5MG BASE/5ML	N61455 001	
	PATHOCIL			
AB +	WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001	
AB		EQ 62.5MG BASE/5ML	N50092 001	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL			
AB	LANNETT	10MG	N84285 001	

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BENTYL PRESERVATIVE FREE

AP		HOECHST MARION RSSL	10MG/ML	N08370 002 OCT 15, 1984

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

AB		GENEVA PHARMS	500MG	N74604 001 JUN 10, 1996
AB		PUREPAC PHARM	250MG	N74285 001 MAY 07, 1996
AB			500MG	N74285 002 MAY 07, 1996

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

AP		SANOFI WINTHROP	0.25MG/ML	N40093 001 MAY 16, 1996

DIGOXIN PEDIATRIC

AP		SANOFI WINTHROP	0.1MG/ML	N40092 001 APR 25, 1996

LANOXIN

	+	GLAXO WELLCOME	0.1MG/ML	N09330 004

LANOXIN PEDIATRIC

AP	+	GLAXO WELLCOME	0.1MG/ML	N09330 004

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
CARDIZEM

AP	+	HOECHST MARION RSSL	5MG/ML	N20027 001 OCT 24, 1991

DILTIAZEM HCL

AP		BEDFORD	5MG/ML	N74617 001 FEB 28, 1996

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA		HALSEY	50MG	N87914 001 JUN 04, 1984
	@		50MG	N87914 001 JUN 04, 1984

ELIXIR; ORAL
BELIX

AA		HALSEY	12.5MG/5ML	N86586 001 OCT 03, 1983
	@		12.5MG/5ML	N86586 001 OCT 03, 1983

DIBENIL

AA		CENCI	12.5MG/5ML	N88304 001 DEC 16, 1983
	@		12.5MG/5ML	N88304 001 DEC 16, 1983

DIPHENHYDRAMINE HCL

AA		CENCI	12.5MG/5ML	N87941 001 DEC 17, 1982
	@		12.5MG/5ML	N87941 001 DEC 17, 1982

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

B*		KV PHARM	EQ 100MG BASE	N71929 001 AUG 19, 1988
	@		EQ 100MG BASE	N71929 001 AUG 19, 1988

NORPACE CR

AB		SEARLE	EQ 100MG BASE	N18655 001 JUL 20, 1982
			EQ 100MG BASE	N18655 001 JUL 20, 1982

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

>ADD>	AP		ABBOTT	EQ 1.25GM BASE/100ML	N74634 001 SEP 27, 1996
>ADD>					

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

> ADD >	AP	ELKINS SINN	EQ 12.5MG BASE/ML	N74381 001 SEP 26, 1996
> ADD				

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE

+	RHONE POULENC	EQ 40MG BASE/ML	N20449 001 MAY 14, 1996

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	SANOFI WINTHROP	40MG/ML	N74403 001 MAY 23, 1996

DOXYCYCLINE HYCLATE

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	SUPERPHARM	EQ 100MG BASE	N62494 001 FEB 20, 1985
@		EQ 100MG BASE	N62494 001 FEB 20, 1985

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP	STERIS	10MG/ML	N40044 001 MAR 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

AP	STERIS	10MG/ML	N40043 001 MAR 20, 1996

TENSILON PRESERVATIVE FREE

AP +	ROCHE	10MG/ML	N07959 002

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID

@	BRISTOL	25MG	N18981 002 DEC 24, 1986
@		35MG	N18981 003 DEC 24, 1986
	BRISTOL MYERS SQUIBB	25MG	N18981 002 DEC 24, 1986
		35MG	N18981 003 DEC 24, 1986

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE

AP	ABBOTT	0.01MG/ML;1%	N83154 001
@		0.01MG/ML;1%	N83154 001

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AT	ADV REMEDIES	0.5%	N64030 001 JUL 18, 1996

SWAB; TOPICAL
ERYTHROMYCIN

AT	STIEFEL	2%	N64126 001 JUL 03, 1996
AT		2%	N64128 001 JUL 03, 1996

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ILOSONE

AB	DISTA	EQ 125MG BASE/5ML	N61894 001
AB +		EQ 250MG BASE/5ML	N61894 002
@		EQ 125MG BASE/5ML	N61894 001
@		EQ 250MG BASE/5ML	N61894 002
AB	LILLY	EQ 125MG BASE/5ML	N50010 001
AB +		EQ 250MG BASE/5ML	N50010 002

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

	ERYTHROCIN			
AP	ABBOTT	EQ 500MG BASE/VIAL	N62586 001	JAN 04, 1988
AP		EQ 1GM BASE/VIAL	N62586 002	JAN 04, 1988
@		EQ 500MG BASE/VIAL	N62586 001	JAN 04, 1988
@		EQ 1GM BASE/VIAL	N62586 002	JAN 04, 1988

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	ESTRADIOL			
AB	MENOREST	0.0375MG/24HR	N20538 001	JUL 31, 1996
AB		0.05MG/24HR	N20538 003	JUL 31, 1996
AB		0.075MG/24HR	N20538 002	JUL 31, 1996
AB		0.1MG/24HR	N20538 004	JUL 31, 1996
	VIVELLE			
AB +	CIBA GEIGY	0.0375MG/24HR	N20323 001	OCT 28, 1994
AB +		0.05MG/24HR	N20323 002	OCT 28, 1994
AB +		0.075MG/24HR	N20323 003	OCT 28, 1994
AB +		0.1MG/24HR	N20323 004	OCT 28, 1994

INSERT, EXTENDED RELEASE; VAGINAL

	ESTRING			
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N20472 001	APR 26, 1996

TABLET; ORAL

	ESTRACE			
AB	BRISTOL MYERS SQUIBB	0.5MG	N81295 001	JUN 30, 1993
AB		1MG	N84499 001	
AB +		2MG	N84500 001	
	ESTRADIOL			
AB	WATSON LABS	0.5MG	N40114 003	MAR 14, 1996

ESTRADIOL

TABLET; ORAL

	ESTRADIOL			
AB	WATSON LABS	1MG	N40114 001	MAR 14, 1996
AB		2MG	N40114 002	MAR 14, 1996

ESTRONE

INJECTABLE; INJECTION

	ESTROGENIC SUBSTANCE			
BP +	WYETH AYERST	2MG/ML	N83488 001	
@		2MG/ML	N83488 001	
	NATURAL ESTROGENIC SUBSTANCE-ESTRONE			
BP	STERIS	2MG/ML	N85237 001	NOV 23, 1982
+		2MG/ML	N85237 001	NOV 23, 1982

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-21			
AB	WATSON LABS	0.035MG;1MG	N72720 001	DEC 30, 1991
	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-21			
AB	WATSON LABS	0.05MG;1MG	N72722 001	DEC 30, 1991
	ZOVIA 1/35E-21			
AB	WATSON LABS	0.035MG;1MG	N72720 001	DEC 30, 1991
	ZOVIA 1/50E-21			
AB	WATSON LABS	0.05MG;1MG	N72722 001	DEC 30, 1991

TABLET; ORAL-28

	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-28			
AB	WATSON LABS	0.035MG;1MG	N72721 001	DEC 30, 1991
	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-28			
AB	WATSON LABS	0.05MG;1MG	N72723 001	DEC 30, 1991
	ZOVIA 1/35E-28			
AB	WATSON LABS	0.035MG;1MG	N72721 001	DEC 30, 1991

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28
ZOVIA 1/50E-28

AB	WATSON LABS	0.05MG;1MG	N72723 001	DEC 30, 1991

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001	SEP 24, 1991
AB	+	0.035MG,0.035MG;0.5MG,1MG	N71041 001	SEP 24, 1991

ORTHO-NOVUM 7/14-21

AB	+ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004 001	APR 04, 1984
	@	0.035MG,0.035MG;0.5MG,1MG	N19004 001	APR 04, 1984

ETODOLAC

TABLET; ORAL
LODINE

	+ WYETH AYERST	400MG	N18922 004	JUL 29, 1993
		400MG	N18922 004	JUL 29, 1993
	+	500MG	N18922 005	JUN 28, 1996

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	GENSIA	20MG/ML	N74529 001	JUL 24, 1996
AP	IMMUNEX	20MG/ML	N74513 001	MAR 14, 1996
AP	LEDERLE	20MG/ML	N74513 001	MAR 14, 1996
AP	PHARMACHEMIE (NL)	20MG/ML	N74227 001	FEB 22, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001	MAY 17, 1996

EVANS BLUE

INJECTABLE; INJECTION
EVANS BLUE

@	PARKE DAVIS	0.5%	N08041 001	

FAMCICLOVIR

TABLET; ORAL
FAMVIR

	SMITHKLINE BEECHAM	250MG	N20363 001	APR 26, 1996

FAMOTIDINE

INJECTABLE; INJECTION
PEPCID IV PRESERVATIVE FREE

+	MERCK	10MG/ML	N19510 004	NOV 04, 1986

PEPCID PRESERVATIVE FREE

+	MERCK	10MG/ML	N19510 004	NOV 04, 1986

FERUMOXIDES

INJECTABLE; INJECTION
FERIDEX I.V.

+	ADV MAGNETICS	EQ 11.2MG IRON/ML	N20416 001	AUG 30, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL
ALLEGRA

+	HOECHST MARION RSSL	60MG	N20625 001	JUL 25, 1996

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
@ 3M — 200MG — N18830 002 OCT 31, 1985

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	+ HAMILTON PHARMA CA	0.01%	N12787 004	
AT	+	0.025%	N12787 002	
AT	+	0.025%	N12787 005	
	+	0.2%	N16161 002	
	SYNALAR			
AT	+ SYNTEX	0.01%	N12787 004	
AT	+	0.025%	N12787 002	
AT	+	0.025%	N12787 005	
	SYNALAR-HP			
	+ SYNTEX	0.2%	N16161 002	

OINTMENT; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	+ HAMILTON PHARMA CA	0.025%	N13960 001	
	SYNALAR			
AT	+ SYNTEX	0.025%	N13960 001	

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	+ HAMILTON PHARMA CA	0.01%	N15296 001	
	SYNALAR			
AT	+ SYNTEX	0.01%	N15296 001	

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	+ HAMILTON PHARMA CA	0.05%	N16908 002	> ADD >
	FLUOCINONIDE EMOLLIENT BASE			> ADD >
AB	HAMILTON PHARMA CA	0.05%	N16908 003	
	LIDEX			
AB	+ SYNTEX	0.05%	N16908 002	
	LIDEX-E			
AB	SYNTEX	0.05%	N16908 003	

GEL; TOPICAL

	FLUOCINONIDE			> ADD >
AB	+ HAMILTON PHARMA CA	0.05%	N17373 001	> ADD >

FLUOCINONIDE

GEL; TOPICAL

	LIDEX			
AB	+ SYNTEX	0.05%	N17373 001	

OINTMENT; TOPICAL

FLUOCINONIDE			
AB	+ HAMILTON PHARMA CA	0.05%	N16909 002
LIDEX			
AB	+ SYNTEX	0.05%	N16909 002

SOLUTION; TOPICAL

FLUOCINONIDE			
AT	+ HAMILTON PHARMA CA	0.05%	N18849 001 APR 06, 1984
LIDEX			
AT	+ SYNTEX	0.05%	N18849 001 APR 06, 1984

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL			
AP	+ PHARMACIA	50MG/ML	N40023 001 OCT 18, 1991
AP	PHARMACIA AND UPJOHN	50MG/ML	N40023 001 OCT 18, 1991
FLUOROURACIL			
AP	ROCHE	50MG/ML	N12209 001
AP	+	50MG/ML	N12209 001

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE			
AO	BEDFORD	25MG/ML	N74531 001 AUG 30, 1996
AO	GENSIA	25MG/ML	N74795 001 SEP 10, 1996

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HCL			
AA	PHARM ASSOC	5MG/ML	N74725 001 SEP 16, 1996

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL
FLUPHENAZINE HCL

AA	PHARM ASSOC	2.5MG/5ML	N40146 001 AUG 21, 1996

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

AB	SUPERPHARM	15MG	N71659 001 AUG 04, 1988
AB		30MG	N71660 001 AUG 04, 1988
@		15MG	N71659 001 AUG 04, 1988
@		30MG	N71660 001 AUG 04, 1988
AB	WARNER CHILCOTT	15MG	N71767 001 DEC 04, 1987
AB		30MG	N71768 001 DEC 04, 1987
@		15MG	N71767 001 DEC 04, 1987
@		30MG	N71768 001 DEC 04, 1987

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION
FLOVENT

	GLAXO WELLCOME	0.044MG/INH	N20548 001 MAR 27, 1996
		0.11MG/INH	N20548 002 MAR 27, 1996
+		0.22MG/INH	N20548 003 MAR 27, 1996

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA	HALSEY	1MG	N83598 001
@		1MG	N83598 001

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
CEREBYX

+	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N20450 001 AUG 05, 1996

FUROSEMIDE

TABLET; ORAL
FUROSEMIDE

AB	SUPERPHARM	20MG	N18370 002 JUN 26, 1984
AB		40MG	N18370 001 FEB 10, 1983
@		20MG	N18370 002 JUN 26, 1984
@		40MG	N18370 001 FEB 10, 1983
AB	ZENITH GOLDLINE	20MG	N18413 001 NOV 30, 1983
AB		40MG	N18413 002 NOV 30, 1983
AB	ZENITH LABS	20MG	N18413 001 NOV 30, 1983
AB		40MG	N18413 002 NOV 30, 1983

GANCICLOVIR

IMPLANT; IMPLANTATION
VITRASERT

+	CHIRON VISION	4.5-6.4MG	N20569 001 MAR 04, 1996
+		4.5MG	N20569 001 MAR 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
CYTOVENE IV

+	ROCHE	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989
+	SYNTEX	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMZAR

+	LILLY	EQ 200MG BASE/VIAL	N20509 001	MAY 15, 1996
+		EQ 1GM BASE/VIAL	N20509 002	MAY 15, 1996

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	ABBOTT	**EQ 60MG BASE/100ML**	**N62413 006**	AUG 11, 1983
AP		**EQ 70MG BASE/100ML**	**N62413 007**	AUG 11, 1983
AP		**EQ 80MG BASE/100ML**	**N62413 008**	AUG 11, 1983
AP		**EQ 90MG BASE/100ML**	**N62413 009**	AUG 11, 1983
AP		**EQ 100MG BASE/100ML**	**N62413 010**	AUG 11, 1983
AP		**EQ 1.2MG BASE/ML**	**N62413 001**	AUG 11, 1983
AP		**EQ 1.4MG BASE/ML**	**N62413 002**	AUG 11, 1983
AP		**EQ 1.6MG BASE/ML**	**N62413 003**	AUG 11, 1983
AP		**EQ 1.8MG BASE/ML**	**N62413 004**	AUG 11, 1983
AP		**EQ 2MG BASE/ML**	**N62413 005**	AUG 11, 1983
	@	EQ 60MG BASE/100ML	N62413 006	AUG 11, 1983
	@	EQ 70MG BASE/100ML	N62413 007	AUG 11, 1983
	@	EQ 80MG BASE/100ML	N62413 008	AUG 11, 1983
	@	EQ 90MG BASE/100ML	N62413 009	AUG 11, 1983
	@	EQ 100MG BASE/100ML	N62413 010	AUG 11, 1983
	@	EQ 1.2MG BASE/ML	N62413 001	AUG 11, 1983
	@	EQ 1.4MG BASE/ML	N62413 002	AUG 11, 1983

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

	@ ABBOTT	EQ 1.6MG BASE/ML	N62413 003	AUG 11, 1983
	@	EQ 1.8MG BASE/ML	N62413 004	AUG 11, 1983
	@	EQ 2MG BASE/ML	N62413 005	AUG 11, 1983

OINTMENT; OPHTHALMIC
GENTACIDIN

AT	CIBA	**EQ 0.3% BASE**	**N62501 001**	JUL 26, 1984
AT	IOLAB	**EQ 0.3% BASE**	**N62501 001**	JUL 26, 1984

SOLUTION/DROPS; OPHTHALMIC
GENTACIDIN

AT	CIBA	**EQ 0.3% BASE**	**N62480 001**	MAR 30, 1984
AT	IOLAB	**EQ 0.3% BASE**	**N62480 001**	MAR 30, 1984

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	NOVOPHARM	**5MG**	**N74387 001**	MAR 04, 1996
AB		**10MG**	**N74387 002**	MAR 04, 1996

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

	HALSEY	250MG	N89458 001	OCT 10, 1986
	@	250MG	N89458 001	OCT 10, 1986

GLYBURIDE

TABLET; ORAL

		GLYNASE			
AB		PHARMACIA AND UPJOHN	3MG	N20051 002	
				MAR 04, 1992	
	+		6MG	N20051 004	
				SEP 24, 1993	
AB	+	UPJOHN	3MG	N20051 002	
				MAR 04, 1992	
	@		6MG	N20051 004	
				SEP 24, 1993	

GLYCOPYRROLATE

INJECTABLE; INJECTION

		GLYCOPYRROLATE			
AP		ABBOTT	0.2MG/ML	N89393 001	
				JUN 15, 1988	
	@		0.2MG/ML	N89393 001	
				JUN 15, 1988	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

		ZOLADEX			
	+	ZENECA	EQ 10.8MG BASE	N20578 001	
				JAN 11, 1996	> DLT >

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

		NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			> DLT >
AT		BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N64047 001	> DLT >
				JAN 31, 1996	

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

		HALDOL DECANOATE 100			
	+	JOHNSON RW	EQ 100MG BASE/ML	N18701 002	
				OCT 31, 1989	

HALOPROGIN

CREAM; TOPICAL

		HALOTEX			
	+	WESTWOOD SQUIBB	1%	N16942 001	
	@		1%	N16942 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

		HEPARIN LOCK FLUSH			
AP		SOLOPAK	100 UNITS/ML	N87905 001	
				APR 20, 1983	
	@		100 UNITS/ML	N87905 001	
				APR 20, 1983	
		HEPARIN SODIUM			
AP		LILLY	1,000 UNITS/ML	N05521 001	
AP			20,000 UNITS/ML	N05521 004	
	@		1,000 UNITS/ML	N05521 001	
	@		20,000 UNITS/ML	N05521 004	
AP		MARSAM	1,000 UNITS/ML	N40007 001	
				JUN 07, 1996	
AP		ORGANON	1,000 UNITS/ML	N00552 008	
AP			5,000 UNITS/ML	N00552 009	
AP			10,000 UNITS/ML	N00552 010	
	@		1,000 UNITS/ML	N00552 008	
	@		5,000 UNITS/ML	N00552 009	
	@		10,000 UNITS/ML	N00552 010	
AP		PHARM SPEC ASSOC	20,000 UNITS/ML	N17780 004	> ADD >
	@		1,000 UNITS/ML	N17780 001	> ADD >
	@		5,000 UNITS/ML	N17780 002	> ADD >
	@		10,000 UNITS/ML	N17780 003	> ADD >
	@		20,000 UNITS/ML	N17780 004	> DLT >
AP		PHARM SPECLTS ASSOC	1,000 UNITS/ML	N17780 001	> DLT >
AP			5,000 UNITS/ML	N17780 002	> DLT >
AP			10,000 UNITS/ML	N17780 003	
AP		SANOFI WINTHROP	10,000 UNITS/ML	N40095 001	
				JUL 26, 1996	
AP		SOLOPAK	1,000 UNITS/ML	N87043 001	
AP			5,000 UNITS/ML	N87077 001	
AP			10,000 UNITS/ML	N87107 001	
AP			5,000 UNITS/0.5ML	N87395 001	
	@		1,000 UNITS/ML	N87043 001	
	@		5,000 UNITS/ML	N87077 001	
	@		10,000 UNITS/ML	N87107 001	
	@		5,000 UNITS/0.5ML	N87395 001	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	**5,000 UNITS/100ML**	**N19134 001**
			MAR 29, 1985
	@	5,000 UNITS/100ML	N19134 001
			MAR 29, 1985

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL

AA	HALSEY	**10MG**	**N89218 001**
			JAN 22, 1986
	@	10MG	N89218 001
			JAN 22, 1986

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDRO-D

AB	HALSEY	**25MG**	**N86504 001**
AB		**50MG**	**N83891 002**
	@	25MG	N86504 001
	@	50MG	N83891 002

HYDROCHLOROTHIAZIDE

AB	BARR	**50MG**	**N84771 001**
	@	50MG	N84771 001
AB	SUPERPHARM	**25MG**	**N88827 001**
			DEC 28, 1984
AB		**50MG**	**N88828 001**
			DEC 28, 1984
AB		**100MG**	**N88829 001**
			DEC 28, 1984
	@	25MG	N88827 001
			DEC 28, 1984
	@	50MG	N88828 001
			DEC 28, 1984
	@	100MG	N88829 001 > DLT >
			DEC 28, 1984 > DLT >
			> ADD >
			> ADD >

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	NOVOPHARM	**15MG;250MG**	**N71819 001**
			APR 08, 1988
AB		**25MG;250MG**	**N71820 001**
			APR 08, 1988
AB		**30MG;500MG**	**N71821 001**
			APR 08, 1988
AB		**50MG;500MG**	**N71822 001**
			APR 08, 1988
	@	15MG;250MG	N71819 001
			APR 08, 1988
	@	25MG;250MG	N71820 001
			APR 08, 1988
	@	30MG;500MG	N71821 001
			APR 08, 1988
	@	50MG;500MG	N71822 001
			APR 08, 1988
AB	PARKE DAVIS	**15MG;250MG**	**N71897 001**
			NOV 23, 1987
AB		**25MG;250MG**	**N71898 001**
			NOV 23, 1987
AB		**30MG;500MG**	**N71899 001**
			NOV 23, 1987
AB		**50MG;500MG**	**N71900 001**
			NOV 23, 1987
	@	15MG;250MG	N71897 001
			NOV 23, 1987
	@	25MG;250MG	N71898 001
			NOV 23, 1987
	@	30MG;500MG	N71899 001
			NOV 23, 1987
	@	50MG;500MG	N71900 001
			NOV 23, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	WARNER CHILCOTT	**25MG;40MG**	**N71771 001**
			JAN 26, 1988
	@	25MG;40MG	N71771 001
			JAN 26, 1988

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	DYAZIDE			
AB	+ SMITHKLINE BEECHAM	25MG;37.5MG	N16042 003	MAR 03, 1994
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	MYLAN	25MG;37.5MG	N74701 001	JUN 07, 1996

TABLET; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	SIDMAK LABS NJ	25MG;37.5MG	N74026 001	APR 26, 1996
AB		50MG;75MG	N73467 001	JAN 31, 1996

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
AT	AMBIX	1%	N86080 001	
AT		2.5%	N86271 001	
	@	1%	N86080 001	
	@	2.5%	N86271 001	

OINTMENT; TOPICAL

	HYDROCORTISONE			
AT	AMBIX	1%	N86079 001	
AT		2.5%	N86272 001	
	@	1%	N86079 001	
	@	2.5%	N86272 001	
	PENECORT			
AT	ALLERGAN HERBERT	2.5%	N88217 001	JUN 06, 1984
	@	2.5%	N88217 001	JUN 06, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

	OTICAIR			
AT	BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N64065 001	AUG 28, 1996

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HYDROCORTISONE ACETATE			
AT	+ CENCI	1%	N80419 001	JAN 25, 1982
	@	1%	N80419 001	JAN 25, 1982
AT	PUREPAC PHARM	1%	N86052 001	
AT	+	1%	N86052 001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-HYDROCORT			
AP	ABBOTT	EQ 100MG BASE/VIAL	N85928 001	
	@	EQ 100MG BASE/VIAL	N85928 001	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	ALPHAREDISOL			
AP	+ MERCK SHARP DOHME	1MG/ML	N80778 001	
	@	1MG/ML	N80778 001	
	HYDROXOCOBALAMIN			
AP	STERIS	1MG/ML	N85528 001	
AP		1MG/ML	N85998 001	
	@	1MG/ML	N85528 001	
	+	1MG/ML	N85998 001	

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

	HYDROXYCHLOROQUINE SULFATE			
AB	INVAMED	200MG	N40150 001	JAN 27, 1996

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL			
AP	SOLOPAK	25MG/ML	N86822 001	
AP		50MG/ML	N87310 001	
	@	25MG/ML	N86822 001	
	@	50MG/ML	N87310 001	

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB	HALSEY	10MG	N89366 001 MAY 02, 1988		
@		10MG	N89366 001 MAY 02, 1988		
AB	SUPERPHARM	10MG	N88794 001 DEC 05, 1984		
AB		25MG	N88795 001 DEC 05, 1984		
AB		50MG	N88796 001 DEC 05, 1984		
@		10MG	N88794 001 DEC 05, 1984		
@		25MG	N88795 001 DEC 05, 1984		
@		50MG	N88796 001 DEC 05, 1984		

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

AB	CHELSEA LABS	EQ 25MG HCL	N40156 001 JUL 15, 1996		
AB		EQ 50MG HCL	N40156 002 JUL 15, 1996		

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN

BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989		

IBU

BX	KNOLL PHARM	100MG/5ML	N19784 001 DEC 18, 1989		

MOTRIN

BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989		

RUFEN

BX	KNOLL PHARM	100MG/5ML	N19784 001 DEC 18, 1989	> ADD > > ADD >	

TABLET; ORAL
IBU

AB	KNOLL PHARM	400MG	N18197 001		

IBUPROFEN

TABLET; ORAL
IBU

AB	KNOLL PHARM	400MG	N70083 001 FEB 22, 1985		
AB		600MG	N70088 001 FEB 08, 1985		
AB		600MG	N70099 001 MAR 29, 1985		
AB		800MG	N70745 001 JUL 23, 1986		

IBUPROFEN

AB	HALSEY	300MG	N71028 001 MAR 23, 1987		
AB		400MG	N71029 001 MAR 23, 1987		
AB		600MG	N71030 001 MAR 23, 1987		
AB		800MG	N72137 001 FEB 05, 1988		
@		300MG	N71028 001 MAR 23, 1987		
@		400MG	N71029 001 MAR 23, 1987		
@		600MG	N71030 001 MAR 23, 1987		
@		800MG	N72137 001 FEB 05, 1988		
AB	KNOLL PHARM	400MG	N70083 001 FEB 22, 1985		

RUFEN

AB	KNOLL PHARM	400MG	N18197 001		
AB		600MG	N70088 001 FEB 08, 1985		
AB		600MG	N70099 001 MAR 29, 1985		
AB		800MG	N70745 001 JUL 23, 1986		

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN

+	PHARMACIA AND UPJOHN	20MG/VIAL	N50661 003 APR 25, 1995		

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

AB	EON LABS	10MG	N85200 001
AB		25MG	N84869 002
AB		50MG	N85133 001
@		10MG	N85200 001
@		25MG	N84869 002
@		50MG	N85133 001

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB	INVAMED	1.25MG	N74594 001 MAY 23, 1996
AB		2.5MG	N74594 002 MAY 23, 1996
AB	MYLAN	2.5MG	N74461 001 MAR 27, 1996
AB	PUREPAC PHARM	1.25MG	N74722 001 JUN 17, 1996
AB		2.5MG	N74722 002 JUN 17, 1996
> ADD > AB	WATSON LABS	1.25MG	N74585 001 SEP 26, 1996
> ADD > AB		2.5MG	N74585 002 SEP 26, 1996
AB	ZENITH GOLDLINE	1.25MG	N74299 002 APR 29, 1996
AB		2.5MG	N74299 001 JUL 27, 1995
AB	ZENITH LABS	2.5MG	N74299 001 JUL 27, 1995

LOZOL

AB	RHONE POULENC RORER	1.25MG	N18538 002 APR 29, 1993

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN

	MERCK	EQ 200MG BASE	N20685 003 MAR 13, 1996
+		EQ 400MG BASE	N20685 001 MAR 13, 1996

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	HALSEY	25MG	N70782 001 JUN 03, 1987
AB		50MG	N70635 001 JUN 03, 1987
@		25MG	N70782 001 JUN 03, 1987
@		50MG	N70635 001 JUN 03, 1987
AB	PARKE DAVIS	25MG	N18806 001 NOV 23, 1984
AB		50MG	N18806 002 NOV 23, 1984
@		25MG	N18806 001 NOV 23, 1984
@		50MG	N18806 002 NOV 23, 1984

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG

+	LILLY	100 UNITS/ML	N20563 001 JUN 14, 1996

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270

+	NYCOMED	55%	N20351 001 MAR 22, 1996

VISIPAQUE 320

+	NYCOMED	65.2%	N20351 002 MAR 22, 1996

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-200

@	BRACCO	41%	N20327 001 OCT 12, 1994
@		41%	N20327 001 OCT 12, 1994

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-250
BRACCO 51% N20327 002 OCT 12, 1994
\+ 51% N20327 002 OCT 12, 1994

ISOVUE-300
BRACCO 61% N20327 003 OCT 12, 1994
\+ 61% N20327 003 OCT 12, 1994

ISOVUE-370
BRACCO 76% N20327 004 OCT 12, 1994
\+ 76% N20327 004 OCT 12, 1994

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR
\+ PHARMACIA AND UPJOHN 20MG/ML N20571 001 JUN 14, 1996

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
BP LUITPOLD EQ 50MG IRON/ML N40024 001 FEB 23, 1996

ISONIAZID

TABLET; ORAL
ISONIAZID
AA DANBURY PHARMA 50MG N80522 001
AA 100MG N80523 001
@ 50MG N80522 001
@ 100MG N80523 001
AA DURAMED 100MG N88231 001 MAR 17, 1983
@ 100MG N88231 001 MAR 17, 1983
@ GLOBAL PHARM 100MG N80153 001

ISONIAZID

TABLET; ORAL
ISONIAZID
AA GLOBAL PHARMS 100MG N80153 001
AA HALSEY 50MG N83632 001
@ 50MG N83632 001
AA PHOENIX LABS NY 50MG N80368 001
AA 100MG N80368 002
@ 50MG N80368 001
@ 100MG N80368 002
AA ZENITH LABS 100MG N80270 001
AA 300MG N83610 001
@ 100MG N80270 001
@ 300MG N83610 001
LANIAZID
AA LANNETT 50MG N80140 001
50MG N80140 001

ISOSORBIDE DINITRATE

TABLET; ORAL
SORBITRATE
BX ZENECA 5MG N16192 001 APR 01, 1996
BX 10MG N16192 002 APR 01, 1996

TABLET; SUBLINGUAL
SORBITRATE
BX ZENECA 2.5MG N16191 002 APR 01, 1996
BX 5MG N16191 001 APR 01, 1996

TABLET, CHEWABLE; ORAL
SORBITRATE
ZENECA 5MG N16776 002 APR 01, 1996
\+ 10MG N16776 003 APR 01, 1996

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET
\+ SCHWARZ 10MG N20215 002 JUN 30, 1993

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET
SCHWARZ 10MG N20215 002 JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL
IMDUR
@ SCHERING 30MG N20225 001 AUG 12, 1993
\+ 30MG N20225 001 AUG 12, 1993

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR
AP + PARKE DAVIS EQ 50MG BASE/ML N16812 002
AP + EQ 100MG BASE/ML N16812 003
KETAMINE HCL
AP BEDFORD EQ 50MG BASE/ML N74524 001 MAR 22, 1996
AP EQ 100MG BASE/ML N74524 002 MAR 22, 1996
AP SANOFI WINTHROP EQ 50MG BASE/ML N74549 001 JUN 27, 1996
AP EQ 100MG BASE/ML N74549 002 JUN 27, 1996

LACTULOSE

SOLUTION; ORAL
LACTULOSE
AA PHARM ASSOC 10GM/15ML N74623 001 JUL 30, 1996

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
XALATAN
\+ PHARMACIA AND UPJOHN 0.005% N20597 001 JUN 05, 1996

LEUCOVORIN CALCIUM

POWDER FOR RECONSTITUTION; ORAL
LEUCOVORIN CALCIUM
IMMUNEX EQ 60MG BASE/VIAL N08107 003 JAN 30, 1987
@ EQ 60MG BASE/VIAL N08107 003 JAN 30, 1987

LEVONORGESTREL

IMPLANT; IMPLANTATION
LEVONORGESTREL
WYETH AYERST 75MG/IMPLANT N20627 001 AUG 15, 1996

LIDOCAINE

FILM, EXTENDED RELEASE; BUCCAL
LIDOCAINE
\+ NOVEN 23MG/PATCH N20575 001 MAY 21, 1996
\+ 46.1MG/PATCH N20575 002 MAY 21, 1996

OINTMENT; TOPICAL
ALPHACAINE
>DLT> AT CARLISLE 5% N84944 001
>DLT> AT 5% N84946 001
>ADD> @ 5% N84944 001
>ADD> @ 5% N84946 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
>DLT> ALPHACAINE HCL
>DLT> AP CARLISLE 2% N84721 001
>ADD> @ 2% N84721 001
LIDOCAINE HCL
AP ABBOTT 20% N89362 001 MAY 25, 1988
@ 20% N89362 001 MAY 25, 1988
>DLT> AP DELL LABS 1% N83387 001
>DLT> AP 2% N83388 001
>ADD> @ 1% N83387 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

> ADD >		@	DELL LABS	2%	N83388 001
> DLT >	AP		FUJISAWA	2%	N17508 001
> DLT >	AP			4%	N17508 002
> DLT >	AP			20%	N17508 004
> ADD >		@		2%	N17508 001
> ADD >		@		4%	N17508 002
> ADD >		@		20%	N17508 004
> DLT >	AP		INTL MEDICATION	1%	N17701 002
> DLT >	AP			2%	N17701 001
> ADD >		@		1%	N17701 002
> ADD >		@		2%	N17701 001

SOLUTION; ORAL

LIDOCAINE HCL

AT		MORTON GROVE	2%	N87872 001 NOV 18, 1982

LIDOCAINE HCL VISCOUS

AT		INTL MEDICATION	2%	N86389 001 FEB 02, 1982
	@		2%	N86389 001 FEB 02, 1982

MYLOCAINE

AT		MORTON GROVE	2%	N87872 001 NOV 18, 1982

SOLUTION; TOPICAL

ANESTACON

AT	+	ALCON	2%	N80429 001
AT	+	POLYMEDICA	2%	N80429 001

LIDOCAINE HCL

AT		MORTON GROVE	4%	N87881 001 NOV 18, 1982

MYLOCAINE

AT		MORTON GROVE	4%	N87881 001 NOV 18, 1982

LINDANE

CREAM; TOPICAL

KWELL

	+	REED AND CARNRICK	1%	N06309 001
			1%	N84218 001
	@		1%	N06309 001
	+		1%	N84218 001

LINDANE

LOTION; TOPICAL

KWELL

AT	+	REED AND CARNRICK	1%	N06309 003
AT			1%	N84218 002
AT	+		1%	N84218 002
	@		1%	N06309 003

SHAMPOO; TOPICAL

KWELL

AT	+	REED AND CARNRICK	1%	N10718 001
AT			1%	N84219 001
AT	+		1%	N84219 001
	@		1%	N10718 001

LITHIUM CITRATE

SYRUP; ORAL

CIBALITH-S

AA		SOLVAY	EQ 300MG CARBONATE/5ML	N17672 001
		LITHONATE		
	@	SOLVAY	EQ 300MG CARBONATE/5ML	N17672 001

LORACARBEF

CAPSULE; ORAL

LORABID

+	LILLY	200MG	N50668 001 DEC 31, 1991
		200MG	N50668 001 DEC 31, 1991
+		400MG	N50668 002 APR 05, 1996

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D 24 HOUR

+	SCHERING	10MG;240MG	N20470 001 AUG 23, 1996

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

> ADD >	AP	MARSAM	2MG/ML	N74535 001 SEP 12, 1996
> ADD >				
> ADD >	AP		2MG/ML	N74551 001 SEP 12, 1996
> ADD >				
> ADD >	AP		1MG/0.5ML	N74551 003 SEP 12, 1996
> ADD >				
> ADD >	AP		4MG/ML	N74535 002 SEP 12, 1996
> ADD >				
> ADD >	AP		4MG/ML	N74551 002 SEP 12, 1996
> ADD >				

TABLET; ORAL
LORAZEPAM

AB	HALSEY	0.5MG	N71434 001 SEP 01, 1987
AB		1MG	N71435 001 SEP 01, 1987
AB		2MG	N71436 001 SEP 01, 1987
@		0.5MG	N71434 001 SEP 01, 1987
@		1MG	N71435 001 SEP 01, 1987
@		2MG	N71436 001 SEP 01, 1987
AB	SUPERPHARM	0.5MG	N71245 001 FEB 09, 1987
AB		1MG	N71246 001 FEB 09, 1987
AB		2MG	N71247 001 FEB 09, 1987
@		0.5MG	N71245 001 FEB 09, 1987
@		1MG	N71246 001 FEB 09, 1987
@		2MG	N71247 001 FEB 09, 1987

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER

ABBOTT	EQ 0.1MG MANGANESE/ML	N18962 001 JUN 26, 1986

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER

@ ABBOTT	EQ 0.1MG MANGANESE/ML	N18962 001 JUN 26, 1986

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE

FUJISAWA	EQ 0.1MG MANGANESE/ML	N19228 001 MAY 05, 1987
@	EQ 0.1MG MANGANESE/ML	N19228 001 MAY 05, 1987

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

AB	BARR	EQ 50MG BASE	N72848 001 MAR 20, 1989
AB		EQ 100MG BASE	N72809 001 MAR 20, 1989
@		EQ 50MG BASE	N72848 001 MAR 20, 1989
@		EQ 100MG BASE	N72809 001 MAR 20, 1989

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
MEDROXYPROGESTERONE ACETATE

AB	BARR	2.5MG	N40159 001 AUG 09, 1996
AB		5MG	N40159 002 AUG 09, 1996
AB		10MG	N40159 003 AUG 09, 1996

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	BARR	20MG	N74621 002 AUG 16, 1996

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DEMEROL		
AP	+	SANOFI WINTHROP	25MG/ML	N05010 007
AP	+		50MG/ML	N05010 002
AP	+		75MG/ML	N05010 009
AP	+		100MG/ML	N05010 003
AP	+	STERLING WINTHROP	25MG/ML	N05010 007
AP	+		50MG/ML	N05010 002
AP	+		75MG/ML	N05010 009
AP	+		100MG/ML	N05010 003

SYRUP; ORAL

		DEMEROL		
AA		SANOFI WINTHROP	50MG/5ML	N05010 005
AA		STERLING WINTHROP	50MG/5ML	N05010 005

TABLET; ORAL

		DEMEROL		
AA	+	SANOFI WINTHROP	50MG	N05010 001
AA	+		100MG	N05010 004
AA	+	STERLING WINTHROP	50MG	N05010 001
AA	+		100MG	N05010 004

MEPROBAMATE

CAPSULE, EXTENDED RELEASE; ORAL

		MEPROSPAN		
		WALLACE PHARMS	200MG	N11284 001
	+		400MG	N11284 002
	@		200MG	N11284 001
	@		400MG	N11284 002

TABLET; ORAL

		MEPROBAMATE		
AA		BARR	600MG	N84230 001
	@		600MG	N84230 001
> DLT >	AA	MK LABS	200MG	N14368 004
> DLT >	AA		400MG	N14368 002
> ADD >		@	200MG	N14368 004
> ADD >		@	400MG	N14368 002
		NEURAMATE		
AA		HALSEY	200MG	N14359 002
AA			400MG	N14359 001
	@		200MG	N14359 002
	@		400MG	N14359 001

MEROPENEM

INJECTABLE; INJECTION

		MERREM I.V.		
	+	ZENECA	500MG/VIAL	N50706 003
				JUN 21, 1996
	+		1GM/VIAL	N50706 001
				JUN 21, 1996

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

		METHADOSE		
AA		MALLINCKRODT	10MG/ML	N17116 002
AA	+		10MG/ML	N17116 002

METHAZOLAMIDE

TABLET; ORAL

		METHAZOLAMIDE		
AB		INVAMED	25MG	N40102 001
				AUG 28, 1996
AB			50MG	N40102 002
				AUG 28, 1996

METHYLDOPA

TABLET; ORAL

		METHYLDOPA		
AB		HALSEY	500MG	N71753 001
				MAR 28, 1988
	@		500MG	N71753 001
				MAR 28, 1988
AB		NOVOPHARM	125MG	N71105 001
				DEC 05, 1986
AB			250MG	N71106 001
				DEC 05, 1986
AB			500MG	N71067 001
				DEC 05, 1986
	@		125MG	N71105 001
				DEC 05, 1986
	@		250MG	N71106 001
				DEC 05, 1986
	@		500MG	N71067 001
				DEC 05, 1986

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL

BP	SCHERING	25MG		N03158 002
	@	25MG		N03158 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	ABBOTT	EQ 10MG BASE/2ML		N70505 001 JUN 23, 1989
AP		EQ 5MG BASE/ML		N70505 001 JUN 23, 1989
AP		EQ 10MG BASE/2ML		N70506 001 JUN 22, 1989
AP		EQ 5MG BASE/ML		N70506 001 JUN 22, 1989
AP		EQ 10MG BASE/2ML		N73117 001 JAN 17, 1991
AP		EQ 5MG BASE/ML		N73117 001 JAN 17, 1991
AP		EQ 10MG BASE/2ML		N73118 001 JAN 17, 1991
AP		EQ 5MG BASE/ML		N73118 001 JAN 17, 1991
AP	BULL D	EQ 10MG BASE/2ML		N71990 001 JAN 18, 1989
AP	CETUS BEN VENUE	EQ 10MG BASE/2ML		N72155 001 MAR 30, 1992
AP		EQ 5MG BASE/ML		N72155 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML		N72244 001 MAR 30, 1992
AP		EQ 5MG BASE/ML		N72244 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML		N72247 001 MAY 18, 1992
AP		EQ 5MG BASE/ML		N72247 001 MAY 18, 1992
AP	FAULDING	EQ 10MG BASE/2ML		N70847 001 NOV 07, 1988
AP		EQ 5MG BASE/ML		N70847 001 NOV 07, 1988
AP		EQ 10MG BASE/2ML		N71291 001 MAR 03, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	FAULDING	EQ 5MG BASE/ML		N71291 001 MAR 03, 1989
AP		EQ 5MG BASE/ML		N71990 001 JAN 18, 1989
AP	GENSIA	EQ 10MG BASE/2ML		N73135 001 NOV 27, 1991
AP		EQ 5MG BASE/ML		N73135 001 NOV 27, 1991
AP	SANOFI WINTHROP	EQ 5MG BASE/ML		N74147 001 AUG 02, 1996
AP	SMITH AND NEPHEW	EQ 10MG BASE/2ML		N70623 001 MAR 02, 1987
AP		EQ 5MG BASE/ML		N70623 001 MAR 02, 1987

REGLAN

AP	+ ROBINS AH	EQ 10MG BASE/2ML		N17862 001
AP	+	EQ 5MG BASE/ML		N17862 001

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	HALSEY	EQ 10MG BASE		N70906 001 OCT 28, 1986
	@	EQ 10MG BASE		N70906 001 OCT 28, 1986
AB	SCHERING	EQ 10MG BASE		N70598 001 FEB 02, 1987
	@	EQ 10MG BASE		N70598 001 FEB 02, 1987
AB	SUPERPHARM	EQ 10MG BASE		N70926 001 JUN 26, 1987
	@	EQ 10MG BASE		N70926 001 JUN 26, 1987

METOLAZONE

TABLET; ORAL
MYKROX

FISONS	0.5MG		N19532 001 OCT 30, 1987
MEDEVA PHARMS	0.5MG		N19532 001 OCT 30, 1987

ZAROXOLYN

FISONS	2.5MG		N17386 001
	5MG		N17386 002

METOLAZONE

TABLET; ORAL
ZAROXOLYN
+ FISONS 10MG N17386 003
MEDEVA PHARMS 2.5MG N17386 001
5MG N17386 002
+ 10MG N17386 003

METRONIDAZOLE

GEL; VAGINAL
METROGEL
+ CURATEK 0.75% N20208 001
AUG 17, 1992

METROGEL-VAGINAL
+ CURATEK 0.75% N20208 001
AUG 17, 1992

TABLET; ORAL
METRONIDAZOLE
AB HALSEY **250MG** **N70021 001**
APR 02, 1985
AB **500MG** **N70593 001**
FEB 27, 1986
@ 250MG N70021 001
APR 02, 1985
@ 500MG N70593 001
FEB 27, 1986
AB ZENITH GOLDLINE **250MG** **N18517 001**
AB **500MG** **N18517 002**
MAY 05, 1982
AB ZENITH LABS **250MG** **N18517 001**
AB **500MG** **N18517 002**
MAY 05, 1982

> ADD > METYRAPONE

> ADD > CAPSULE; ORAL
> ADD > METOPIRONE
> ADD > + CIBA 250MG N12911 002
> ADD > AUG 09, 1996

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL
AB GENEVA PHARMS **150MG** **N74450 001**
MAY 16, 1996
AB **200MG** **N74450 002**
MAY 16, 1996
AB **250MG** **N74450 003**
MAY 16, 1996

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK
+ JOHNSON RW 2%,200MG N18888 002
OCT 17, 1988

> ADD > MIDODRINE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > PROAMATINE
> ADD > ROBERTS LABS 2.5MG N19815 001
> ADD > SEP 06, 1996
> ADD > + 5MG N19815 002
> ADD > SEP 06, 1996

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL
LEDERLE EQ 100MG BASE N50451 002
AUG 10, 1982
+ EQ 100MG BASE N50451 002
AUG 10, 1982

MINOXIDIL

SOLUTION; TOPICAL
ROGAINE
+ UPJOHN 2% N19501 001
AUG 17, 1988

MIRTAZAPINE

TABLET; ORAL
REMERON
ORGANON 15MG N20415 001 JUN 14, 1996
\+ 30MG N20415 002 JUN 14, 1996

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN
\+ FAULDING SVCS 20MG N20616 001 JUL 03, 1996
\+ 50MG N20616 002 JUL 03, 1996
\+ 100MG N20616 003 JUL 03, 1996

INJECTABLE; INJECTION
MORPHINE SULFATE
AP MALLINCKRODT **1MG/ML** **N20631 001** JUL 03, 1996
\+ 2MG/ML N20631 002 JUL 03, 1996

NADOLOL

TABLET; ORAL
NADOLOL
AB ZENITH GOLDLINE **20MG** **N74229 001** AUG 30, 1996
AB **40MG** **N74229 002** AUG 30, 1996
AB **80MG** **N74255 001** JAN 24, 1996
AB **120MG** **N74255 002** JAN 24, 1996
AB **160MG** **N74255 003** JAN 24, 1996
AB ZENITH LABS **80MG** **N74255 001** JAN 24, 1996
AB **120MG** **N74255 002** JAN 24, 1996
AB **160MG** **N74255 003** JAN 24, 1996

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
ABBOTT 1.5MG/ML N20200 001 MAR 12, 1993

NALBUPHINE HYDROCHLORIDE
ABBOTT 1.5MG/ML N20200 001 MAR 12, 1993

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
AP SMITH AND NEPHEW **0.4MG/ML** **N71682 001** NOV 17, 1987
@ 0.4MG/ML N71682 001 NOV 17, 1987

NAPROXEN

TABLET; ORAL
NAPROXEN
AB BIOCRAFT **250MG** **N74216 001** APR 11, 1996
AB **375MG** **N74216 002** APR 11, 1996
AB **500MG** **N74216 003** APR 11, 1996
AB SIDMAK LABS NJ **250MG** **N74182 001** JUN 27, 1996
AB **375MG** **N74182 002** JUN 27, 1996
AB **500MG** **N74182 003** JUN 27, 1996

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
AB AL HIKMA **EQ 500MG BASE** **N74480 001** MAY 14, 1996
AB SIDMAK LABS NJ **EQ 250MG BASE** **N74242 001** JUN 20, 1996
AB **EQ 500MG BASE** **N74242 002** JUN 20, 1996

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	WEST WARD PHARM	**EQ 500MG BASE**	**N74480 001**	
			MAY 14, 1996	

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN			
+	ELAN PHARM	EQ 375MG BASE	N20353 001	
			JAN 05, 1996	
+		EQ 500MG BASE	N20353 002	
			JAN 05, 1996	
+		EQ 750MG BASE	N20353 003	
			JAN 05, 1996	

NEOMYCIN SULFATE

INJECTABLE; INJECTION

	MYCIFRADIN			
AP	+ UPJOHN	**EQ 350MG BASE/VIAL**	**N60477 001**	
	NEOMYCIN SULFATE			
AP	PFIZER	**EQ 350MG BASE/VIAL**	**N61084 001**	
AP	SQUIBB	**EQ 350MG BASE/VIAL**	**N60366 001**	

POWDER; FOR RX COMPOUNDING

	NEO-RX			
AA	PHARMA TEK	**100%**	**N61579 001**	
		100%	N61579 001	
	NEOMYCIN SULFATE			
	@ ELKINS SINN	100%	N61698 001	
AA	PADDOCK	**100%**	**N62385 001**	
			JUN 01, 1982	

NEVIRAPINE

TABLET; ORAL

	VIRAMUNE			
+	BOEHRINGER INGELHEIM	200MG	N20636 001	
			JUN 21, 1996	

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

	CARDENE			
AB	SYNTEX	**20MG**	**N19488 001**	
			DEC 21, 1988	

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

	CARDENE			
AB	+ SYNTEX	**30MG**	**N19488 002**	
			DEC 21, 1988	
	NICARDIPINE HCL			
AB	MYLAN	**20MG**	**N74642 001**	
			JUL 18, 1996	
AB		**30MG**	**N74642 002**	
			JUL 18, 1996	

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

	NICLOCIDE			
+	BAYER	500MG	N18669 001	
			MAY 14, 1982	
	@	500MG	N18669 001	
			MAY 14, 1982	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	HABITROL			
BC	+ CIBA	7MG/24HR	N20076 001	
			NOV 27, 1991	
BC	+	14MG/24HR	N20076 002	
			NOV 27, 1991	
BC	+	21MG/24HR	N20076 003	
			NOV 27, 1991	
	+	7MG/24HR	N20076 001	
			NOV 27, 1991	
	+	14MG/24HR	N20076 002	
			NOV 27, 1991	
	+	21MG/24HR	N20076 003	
			NOV 27, 1991	
	NICODERM			
BC	+ HOECHST MARION RSSL	7MG/24HR	N20165 001	
			NOV 07, 1991	
BC	+	14MG/24HR	N20165 002	
			NOV 07, 1991	
BC	+	21MG/24HR	N20165 003	
			NOV 07, 1991	

SPRAY, METERED; NASAL

	NICOTROL			
+	PHARMACIA AND UPJOHN	0.5MG/INH	N20385 001	
			MAR 22, 1996	

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

	NICORETTE			
	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001	JAN 13, 1984
	NICORETTE DS			
	+ SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001	JUN 08, 1992

> ADD > NILUTAMIDE

> ADD > TABLET; ORAL

> ADD >	NILANDRON			
> ADD >	+ ROUSSEL UCLAF	50MG	N20169 001	SEP 19, 1996

NITROFURANTOIN

SUSPENSION; ORAL

	FURADANTIN			
	+ DURA	25MG/5ML	N09175 001	
	+ PROCTER AND GAMBLE	25MG/5ML	N09175 001	

NITROFURAZONE

OINTMENT; TOPICAL

	NITROFURAZONE			
AT	AMBIX	**0.2%**	**N86077 001**	
	@	0.2%	N86077 001	

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN			
AB1	3M	**0.1MG/HR**	**N89771 001**	AUG 30, 1996
AB1		**0.2MG/HR**	**N89772 001**	AUG 30, 1996
AB1		**0.4MG/HR**	**N89773 001**	AUG 30, 1996
AB1		**0.6MG/HR**	**N89774 001**	AUG 30, 1996
	NITRO-DUR			
BX	+	0.1MG/HR	N20145 001	APR 04, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITRO-DUR			
BX	+	0.2MG/HR	N20145 002	APR 04, 1995
BX	+	0.4MG/HR	N20145 004	APR 04, 1995
BX	+	0.6MG/HR	N20145 005	APR 04, 1995
AB1	+ KEY PHARMS	**0.1MG/HR**	**N20145 001**	APR 04, 1995
AB1	+	**0.2MG/HR**	**N20145 002**	APR 04, 1995
AB1	+	**0.4MG/HR**	**N20145 004**	APR 04, 1995
AB1	+	**0.6MG/HR**	**N20145 005**	APR 04, 1995
BX	+	0.8MG/HR	N20145 006	APR 04, 1995
	NITROGLYCERIN			
AB2	MYLAN	**0.2MG/HR**	**N74609 001**	AUG 30, 1996
AB2		**0.4MG/HR**	**N74607 001**	AUG 30, 1996
AB2		**0.6MG/HR**	**N74559 001**	AUG 30, 1996
	TRANSDERM-NITRO			
BX	+	0.2MG/HR	N20144 002	FEB 27, 1996
BX	+	0.4MG/HR	N20144 003	FEB 27, 1996
BX	+	0.6MG/HR	N20144 004	FEB 27, 1996
AB2	+ CIBA	**0.2MG/HR**	**N20144 002**	FEB 27, 1996
AB2	+	**0.4MG/HR**	**N20144 003**	FEB 27, 1996
AB2	+	**0.6MG/HR**	**N20144 004**	FEB 27, 1996
BX		0.1MG/HR	N20144 001	FEB 27, 1996
BX	+	0.1MG/HR	N20144 001	FEB 27, 1996
BX		0.8MG/HR	N20144 005	FEB 27, 1996
BX	+	0.8MG/HR	N20144 005	FEB 27, 1996

NORETHINDRONE

TABLET; ORAL
NOR-Q.D.
SEARLE 0.35MG N17060 001
NOR-QD
+ SEARLE 0.35MG N17060 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
AB BIOCRAFT **EQ 10MG BASE** **N73667 001**
APR 11, 1996
AB **EQ 25MG BASE** **N73667 002**
APR 11, 1996
AB **EQ 50MG BASE** **N73667 003**
APR 11, 1996
AB **EQ 75MG BASE** **N73667 004**
APR 11, 1996

NYSTATIN

POWDER; TOPICAL
MYCOSTATIN
AT + WESTWOOD SQUIBB **100,000 UNITS/GM** **N60578 001**
NYSTOP
AT PADDOCK **100,000 UNITS/GM** **N64118 001**
AUG 16, 1996

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYCOLOG-II
AT + APOTHECON **100,000 UNITS/GM;0.1%** **N60576 002**
MAY 01, 1985
> DLT > **AT** **100,000 UNITS/GM;0.1%** **N62606 001**
> DLT >
MAY 15, 1985
> ADD > **AT** + **100,000 UNITS/GM;0.1%** **N62606 001**
> ADD >
MAY 15, 1985
@ 100,000 UNITS/GM;0.1% N60576 002
MAY 01, 1985

> ADD > OLANZAPINE

> ADD > TABLET; ORAL
> ADD > ZYPREXA
> ADD > @ LILLY 2.5MG N20592 001
> ADD >
SEP 30, 1996
> ADD > 5MG N20592 002
> ADD >
SEP 30, 1996
> ADD > 7.5MG N20592 003
> ADD >
SEP 30, 1996
> ADD > + 10MG N20592 004
> ADD >
SEP 30, 1996

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFRAN PRESERVATIVE FREE
+ GLAXO WELLCOME EQ 2MG BASE/ML N20007 003
DEC 10, 1993

OXAZEPAM

TABLET; ORAL
OXAZEPAM
AB PARKE DAVIS **15MG** **N71508 001**
FEB 02, 1987
@ 15MG N71508 001
FEB 02, 1987

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
PARKE DAVIS 100MG/5ML N09268 012
NOV 27, 1984
@ 100MG/5ML N09268 012
NOV 27, 1984

SYRUP; ORAL
CHOLEDYL
PARKE DAVIS 50MG/5ML N09268 011
@ 50MG/5ML N09268 011

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL
+ PARKE DAVIS 100MG N09268 003

OXTRIPHYLLINE

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL

+	PARKE DAVIS	200MG	N09268 007
@		100MG	N09268 003
@		200MG	N09268 007

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN

AA	+ HOECHST MARION RSSL	5MG/5ML	N18211 001

OXYBUTYNIN CHLORIDE

AA	SILARX	5MG/5ML	N74520 001
			MAR 29, 1996

TABLET; ORAL
OXYBUTYNIN CHLORIDE

AB	ROSEMONT	5MG	N74625 001
			JUL 31, 1996

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL

@	SMITHKLINE BEECHAM	EQ 10MG BASE	N20031 001
			DEC 29, 1992
+		EQ 30MG BASE	N20031 003
			DEC 29, 1992
@		EQ 40MG BASE	N20031 005
			DEC 29, 1992
		EQ 10MG BASE	N20031 001
			DEC 29, 1992
		EQ 30MG BASE	N20031 003
			DEC 29, 1992
+		EQ 40MG BASE	N20031 005
			DEC 29, 1992

>ADD> PENCICLOVIR

>ADD> CREAM; TOPICAL
>ADD> DENAVIR
>ADD> + SMITHKLINE BEECHAM 1% N20629 001
>ADD> SEP 24, 1996

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN

>DLT>	AA	BIOCRAFT	400,000 UNITS/5ML	N60307 004
>ADD>			400,000 UNITS/5ML	N60307 004

PFIZERPEN G

>DLT>	AA	PFIZER	400,000 UNITS/5ML	N60587 001
>ADD>		@	400,000 UNITS/5ML	N60587 001

TABLET; ORAL
PENICILLIN G POTASSIUM

>DLT>	AB	MYLAN	800,000 UNITS	N60781 004
>ADD>		+	800,000 UNITS	N60781 004

PFIZERPEN G

>DLT>	AB	PFIZER	200,000 UNITS	N60075 003
>DLT>	AB		250,000 UNITS	N60075 004
>DLT>	AB		400,000 UNITS	N60075 005
>DLT>	AB	+	800,000 UNITS	N60075 006
>DLT>			50,000 UNITS	N60075 001
>DLT>			100,000 UNITS	N60075 002
>ADD>		@	50,000 UNITS	N60075 001
>ADD>		@	100,000 UNITS	N60075 002
>ADD>		@	200,000 UNITS	N60075 003
>ADD>		@	250,000 UNITS	N60075 004
>ADD>		@	400,000 UNITS	N60075 005
>ADD>		@	800,000 UNITS	N60075 006

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PFIZERPEN VK

>DLT>					
>DLT>	AA	PFIZER	EQ 125MG BASE/5ML	N61815 001
>DLT>	AA		EQ 250MG BASE/5ML	N61815 002
>ADD>		@	EQ 125MG BASE/5ML	N61815 001
>ADD>		@	EQ 250MG BASE/5ML	N61815 002

TABLET; ORAL
PFIZERPEN VK

>DLT>					
>DLT>	AB	PFIZER	EQ 250MG BASE	N61836 001
>DLT>	AB		EQ 500MG BASE	N61836 002
>ADD>		@	EQ 250MG BASE	N61836 001
>ADD>		@	EQ 500MG BASE	N61836 002

PENTAMIDINE ISETHIONATE

POWDER FOR RECONSTITUTION; INHALATION
NEBUPENT

	FUJISAWA	600MG/VIAL	N19887 002	MAR 22, 1996

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL

AA	HALSEY	**100MG**	**N84677 001**	
	@	100MG	N84677 001	

> ADD > PENTOSAN POLYSULFATE SODIUM

> ADD > CAPSULE; ORAL
> ADD > ELMIRON

> ADD >	+ BAKER NORTON	100MG	N20193 001	SEP 26, 1996

PERFLUBRON

LIQUID; ORAL
IMAGENT

	+ ALLIANCE PHARM	100%	N20091 001	AUG 13, 1993
	@	100%	N20091 001	AUG 13, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	AMARIC	2MG	N20184 001	DEC 30, 1993
		4MG	N20184 002	DEC 30, 1993
	+	8MG	N20184 003	DEC 30, 1993
	RHONE POULENC RORER	2MG	N20184 001	DEC 30, 1993
		4MG	N20184 002	DEC 30, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	+ RHONE POULENC RORER	8MG	N20184 003	DEC 30, 1993

PHENSUXIMIDE

CAPSULE; ORAL
MILONTIN

	+ PARKE DAVIS	500MG	N08855 004	
	@	500MG	N08855 004	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN

	FISONS	EQ 15MG BASE	N11613 004	
	+	EQ 30MG BASE	N11613 002	
	MEDEVA PHARMS	EQ 15MG BASE	N11613 004	
	+	EQ 30MG BASE	N11613 002	

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE VC

AA	HALSEY	**5MG/5ML;6.25MG/5ML**	**N88868 001**	MAR 02, 1987
	@	5MG/5ML;6.25MG/5ML	N88868 001	MAR 02, 1987

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP	FUJISAWA	**50MG/ML**	**N89003 001**	MAY 31, 1985
	@	50MG/ML	N89003 001	MAY 31, 1985
AP	SOLOPAK	**50MG/ML**	**N88520 001**	DEC 17, 1984
	@	50MG/ML	N88520 001	DEC 17, 1984

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	DANBURY PHARMA	10MG	N74287 001	MAY 16, 1996
AB		20MG	N74287 002	MAY 16, 1996
AB	ZENITH GOLDLINE	10MG	N74148 001	JUN 03, 1996
AB		20MG	N74148 002	JUN 03, 1996

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION
ESTRADURIN

+	WYETH AYERST	40MG/AMP	N10753 001	
@		40MG/AMP	N10753 001	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB	BIOCRAFT	8MEQ	N73531 001	APR 26, 1996
AB		10MEQ	N73532 001	APR 26, 1996

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N87787 001	APR 20, 1982
@		2MEQ/ML	N87787 001	APR 20, 1982

TABLET, EXTENDED RELEASE; ORAL
K-DUR 10

BC	+ KEY PHARMS	10MEQ	N19439 002	JUN 13, 1986
BC	+ SCHERING	10MEQ	N19439 002	JUN 13, 1986

K-DUR 20

+	KEY PHARMS	20MEQ	N19439 001	JUN 13, 1986
+	SCHERING	20MEQ	N19439 001	JUN 13, 1986

PREDNISOLONE

SYRUP; ORAL
PRELONE

MURO	5MG/5ML	N89654 001	JAN 17, 1989
	15MG/5ML	N89081 001	FEB 04, 1986
+	5MG/5ML	N89654 001	JAN 17, 1989
+	15MG/5ML	N89081 001	FEB 04, 1986

PREDNISOLONE ACETATE

SUSPENSION; OPHTHALMIC
PRED FORTE

BX	+ ALLERGAN	1%	N17011 001	

SUSPENSION/DROPS; OPHTHALMIC
PRED FORTE

AB	+ ALLERGAN	1%	N17011 001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULSTER

AT	+ AKORN	EQ 0.23% PHOSPHATE;10%	N74511 001	JUL 30, 1996

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	SUPERPHARM	5MG	N88865 001	OCT 25, 1984
AB		10MG	N88866 001	OCT 25, 1984
AB		20MG	N88867 001	OCT 25, 1984
@		5MG	N88865 001	OCT 25, 1984
@		10MG	N88866 001	OCT 25, 1984
@		20MG	N88867 001	OCT 25, 1984

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCANBID

+	PARKE DAVIS	500MG	N20545 001		
			JAN 31, 1996		
+		1GM	N20545 002		
			JAN 31, 1996		

PROCHLORPERAZINE MALEATE

TABLET; ORAL
COMPAZINE

AB	SMITHKLINE BEECHAM	**EQ 5MG BASE**	**N10571 001**		
AB		**EQ 10MG BASE**	**N10571 002**		
AB	+	**EQ 25MG BASE**	**N10571 003**		
	PROCHLORPERAZINE MALEATE				
AB	COPLEY PHARM	**EQ 5MG BASE**	**N40120 001**		
			JUL 11, 1996		
AB		**EQ 10MG BASE**	**N40120 002**		
			JUL 11, 1996		
AB	INVAMED	**EQ 5MG BASE**	**N40101 001**		
			JUL 19, 1996	> DLT >	
AB		**EQ 10MG BASE**	**N40101 002**	> DLT >	
			JUL 19, 1996	> ADD >	
AB		**EQ 25MG BASE**	**N40101 003**	> ADD >	
			JUL 19, 1996	> ADD >	
				> ADD >	

PROMAZINE HYDROCHLORIDE

TABLET; ORAL
SPARINE

	WYETH AYERST	50MG	N10348 002
+		100MG	N10348 003
+		50MG	N10348 002
@		100MG	N10348 003

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE

AA	CENCI	**6.25MG/5ML**	**N89013 001**
			SEP 20, 1985
@		6.25MG/5ML	N89013 001
			SEP 20, 1985

PROPANTHELINE BROMIDE

TABLET; ORAL
PRO-BANTHINE

AA	+	ROBERTS LABS	**7.5MG**	**N08732 003**
AA	+		**15MG**	**N08732 002**
BP	+		7.5MG	N08732 003
BP	+		15MG	N08732 002
	PROPANTHELINE BROMIDE			
AA		PAR PHARM	**15MG**	**N88377 001**
				DEC 08, 1983
BP			15MG	N88377 001
				DEC 08, 1983
AA		ROXANE	**7.5MG**	**N80927 001**
AA			**15MG**	**N80927 002**
BP			7.5MG	N80927 001
BP			15MG	N80927 002

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN

+	ZENECA	10MG/ML	N19627 001
			OCT 02, 1989
@		10MG/ML	N19627 001
			OCT 02, 1989
+		10MG/ML	N19627 002
			JUN 11, 1996

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPHENE 65

AA	HALSEY	**65MG**	**N83538 002**
@		65MG	N83538 002

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	HALSEY	50MG	N80015 001
@		50MG	N80015 001

PROTIRELIN

INJECTABLE; INJECTION

		THYPINONE		
AP	+	ABBOTT	**0.5MG/ML**	**N17638 001**
	@		0.5MG/ML	N17638 001
		THYREL TRH		
AP		FERRING LABS	**0.5MG/ML**	**N18087 001**
	+		0.5MG/ML	N18087 001

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		NOVAFED		
	+	DOW PHARM	120MG	N17603 001
	+	HOECHST MARION RSSL	120MG	N17603 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

			PYRIDOXINE HCL		
> DLT >	AP		DELL LABS	**100MG/ML**	**N83772 001**
> DLT >				50MG/ML	N83771 001
> ADD >		@		50MG/ML	N83771 001
> ADD >		@		100MG/ML	N83772 001

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

		QUINIDINE GLUCONATE		
AB		HALSEY	**324MG**	**N89476 001 APR 10, 1987**
	@		324MG	N89476 001 APR 10, 1987

QUINIDINE SULFATE

CAPSULE; ORAL

		CIN-QUIN		
AB		SOLVAY	**200MG**	**N85296 001**
			300MG	N85297 001
			200MG	N85296 001
	+		300MG	N85297 001
		QUINIDINE SULFATE		
AB	+	LILLY	**200MG**	**N85103 001**

QUINIDINE SULFATE

CAPSULE; ORAL

		QUINIDINE SULFATE		
	@	LILLY	200MG	N85103 001

TABLET; ORAL

		QUINIDINE SULFATE		
AB		1ST TX	**200MG**	**N85068 001**
AB		BARR	**200MG**	**N84177 001**
	@		200MG	N84177 001
AB		HALSEY	**200MG**	**N83583 001**
	@		200MG	N83583 001
> DLT > AB		ICN	**200MG**	**N83393 001**
> ADD >	@		200MG	N83393 001
AB	+	LILLY	**200MG**	**N85038 001**
	@		200MG	N85038 001
AB		ROXANE	**200MG**	**N83640 001**
AB	+		200MG	N83640 001
AB			**300MG**	**N85632 001**
AB	+		300MG	N85632 001
	@	SCHERER	200MG	N85068 001
		QUINORA		
AB	+	KEY PHARMS	**300MG**	**N85222 001**
	@	SCHERING	300MG	N85222 001

RAMIPRIL

CAPSULE; ORAL

		ALTACE		
		HOECHST MARION RSSL	1.25MG	N19901 001 JAN 28, 1991
			2.5MG	N19901 002 JAN 28, 1991
			5MG	N19901 003 JAN 28, 1991
	+		10MG	N19901 004 JAN 28, 1991
		HOECHST ROUSSEL	1.25MG	N19901 001 JAN 28, 1991
			2.5MG	N19901 002 JAN 28, 1991
			5MG	N19901 003 JAN 28, 1991
	+		10MG	N19901 004 JAN 28, 1991

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC
+ GLAXO WELLCOME 400MG N20559 001 AUG 08, 1996

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA
GLAXO WELLCOME EQ 1MG BASE/VIAL N20630 001 JUL 12, 1996
EQ 2MG BASE/VIAL N20630 002 JUL 12, 1996
+ EQ 5MG BASE/VIAL N20630 003 JUL 12, 1996

RISPERIDONE

SOLUTION; ORAL
RISPERDAL
+ JANSSEN 1MG/ML N20588 001 JUN 10, 1996

RITONAVIR

CAPSULE; ORAL
NORVIR
+ ABBOTT 100MG N20680 001 MAR 01, 1996

SOLUTION; ORAL
NORVIR
ABBOTT 80MG/ML N20659 001 MAR 01, 1996

>ADD> ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

>ADD> INJECTABLE; INJECTION
>ADD> NAROPIN
>ADD> ASTRA 2MG/ML N20533 001 SEP 24, 1996
>ADD> 5MG/ML N20533 003 SEP 24, 1996

>ADD> ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

>ADD> INJECTABLE; INJECTION
>ADD> NAROPIN
>ADD> ASTRA 7.5MG/ML N20533 004 SEP 24, 1996
>ADD> + 10MG/ML N20533 005 SEP 24, 1996

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
+ SOMERSET 5MG N20647 001 MAY 15, 1996

TABLET; ORAL
ELDEPRYL
+ SOMERSET 5MG N19334 001 JUN 05, 1989
@ 5MG N19334 001 JUN 05, 1989

SELEGILINE HCL
AB ENDO LABS **5MG** **N74565 001** AUG 02, 1996
AB LEDERLE **5MG** **N74641 001** AUG 02, 1996
AB NOVOPHARM **5MG** **N74537 001** AUG 02, 1996

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
ZOLOFT
PFIZER EQ 25MG BASE N19839 005 MAR 06, 1996

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP MCGAW **450MG/100ML** **N18184 001**
@ 450MG/100ML N18184 001

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP	MCGAW	**1.87GM/100ML**	**N18186 001**	
	@	1.87GM/100ML	N18186 001	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NIPRIDE

> DLT >				
> DLT >	**AP** + ROCHE	**50MG/VIAL**	**N17546 001**	
> ADD >	@	50MG/VIAL	N17546 001	
	SODIUM NITROPRUSSIDE			
> DLT >	**AP** ELKINS SINN	**50MG/VIAL**	**N18581 001**	
> DLT >			JUL 28, 1982	
> ADD >	**AP** +	**50MG/VIAL**	**N18581 001**	
> ADD >			JUL 28, 1982	

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL

+	UCYCLYD	3GM/TEASPOONFUL	N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL

+	UCYCLYD	500MG	N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
SEROSTIM

BX	SERONO	5MG/VIAL	N20604 002 AUG 23, 1996
+		6MG/VIAL	N20604 001 AUG 23, 1996

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 20%

AP	PHARMACIA AND UPJOHN	**20%**	**N20248 001** AUG 07, 1996

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL
RENORMAX

	SANDOZ	3MG	N20240 001 DEC 29, 1994
		6MG	N20240 002 DEC 29, 1994
		12MG	N20240 003 DEC 29, 1994
+		24MG	N20240 004 DEC 29, 1994
	@ SCHERING	3MG	N20240 001 DEC 29, 1994
	@	6MG	N20240 002 DEC 29, 1994
	@	12MG	N20240 003 DEC 29, 1994
	@	24MG	N20240 004 DEC 29, 1994

SUCRALFATE

TABLET; ORAL
CARAFATE

AB +	BLUE RIDGE	**1GM**	**N18333 001**
	SUCRALFATE		
AB	BIOCRAFT	**1GM**	**N70848 001** MAR 29, 1996

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFATRIM-DS

AB	SUPERPHARM	**800MG;160MG**	**N70066 001** JUN 24, 1985
	@	800MG;160MG	N70066 001 JUN 24, 1985
	SULFATRIM-SS		
AB	SUPERPHARM	**400MG;80MG**	**N70065 002** JUN 24, 1985
	@	400MG;80MG	N70065 002 JUN 24, 1985

SULFISOXAZOLE

TABLET; ORAL

			GANTRISIN		
> DLT >	AB	+	ROCHE	500MG	N06525 001
> ADD >		@		500MG	N06525 001
			SULFISOXAZOLE		
> DLT >	AB		ZENITH LABS	500MG	N80142 001
> ADD >	AB	+		500MG	N80142 001

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX			
@	ZENECA	EQ 20MG BASE	N17970 002 MAR 21, 1994
+		EQ 20MG BASE	N17970 002 MAR 21, 1994

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW			
	MEDI PHYSICS	N/A	N20372 001 FEB 09, 1996

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN			
@	ABBOTT	EQ 1MG BASE	N19057 001 AUG 07, 1987
@		EQ 2MG BASE	N19057 002 AUG 07, 1987
@		EQ 5MG BASE	N19057 003 AUG 07, 1987
@		EQ 10MG BASE	N19057 004 AUG 07, 1987
		EQ 1MG BASE	N19057 001 AUG 07, 1987
+		EQ 2MG BASE	N19057 002 AUG 07, 1987
		EQ 5MG BASE	N19057 003 AUG 07, 1987
		EQ 10MG BASE	N19057 004 AUG 07, 1987

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

LAMISIL			
+	SANDOZ	EQ 250MG BASE	N20539 001 MAY 10, 1996

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL		
AB	SUPERPHARM	250MG	N62540 001 MAR 21, 1985
AB		500MG	N62540 002 MAR 21, 1985
@		250MG	N62540 001 MAR 21, 1985
@		500MG	N62540 002 MAR 21, 1985

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201			
	MEDI PHYSICS	2mCi/ML	N18110 001 FEB 01, 1982
		1mCi/ML	N18110 002 FEB 27, 1996

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOVENT			
BC	SCHERING	125MG	N87010 001 JAN 31, 1985
BC		250MG	N87910 001 JAN 31, 1985
@		125MG	N87010 001 JAN 31, 1985
@		250MG	N87910 001 JAN 31, 1985

ELIXIR; ORAL

ELIXOMIN			
AA	CENCI	80MG/15ML	N88303 001 JAN 25, 1984

THEOPHYLLINE

ELIXIR; ORAL

	ELIXOMIN			
	@ CENCI	80MG/15ML	N88303 001	JAN 25, 1984

INJECTABLE; INJECTION

	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**40MG/100ML**	**N19083 001**	NOV 07, 1984
@		40MG/100ML	N19083 001	NOV 07, 1984
	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**80MG/100ML**	**N19083 002**	NOV 07, 1984
@		80MG/100ML	N19083 002	NOV 07, 1984
	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**160MG/100ML**	**N19083 003**	NOV 07, 1984
@		160MG/100ML	N19083 003	NOV 07, 1984
	THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**200MG/100ML**	**N19826 004**	AUG 14, 1992
@		200MG/100ML	N19826 004	AUG 14, 1992
	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**400MG/100ML**	**N19826 005**	AUG 14, 1992
@		400MG/100ML	N19826 005	AUG 14, 1992

SUSPENSION; ORAL

	ELIXICON			
+	FOREST LABS	100MG/5ML	N85502 001	
@		100MG/5ML	N85502 001	

TABLET, EXTENDED RELEASE; ORAL

	UNI-DUR			
BC +	KEY PHARMS	400MG	N89822 001	JAN 04, 1995
BC +		600MG	N89823 001	JAN 04, 1995
BC +	SCHERING	400MG	N89822 001	JAN 04, 1995
BC +		600MG	N89823 001	JAN 04, 1995

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	UNIPHYL			
BC	PURDUE FREDERICK	600MG	N40086 001	APR 15, 1996

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL			
> DLT > **AP**	DELL LABS	**100MG/ML**	**N83775 001**	
> ADD > @		100MG/ML	N83775 001	
AP	SANOFI WINTHROP	**100MG/ML**	**N40079 001**	MAY 03, 1996

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	MELLARIL			
AA	SANDOZ	**30MG/ML**	**N11808 012**	
AA +		**30MG/ML**	**N11808 012**	
AA		**100MG/ML**	**N11808 018**	
AA +		**100MG/ML**	**N11808 018**	
	THIORIDAZINE HCL			
AA	HI TECH PHARMA	**30MG/ML**	**N40125 001**	AUG 16, 1996
AA		**100MG/ML**	**N40126 001**	AUG 16, 1996

TABLET; ORAL

	THIORIDAZINE HCL			
AB	SUPERPHARM	**10MG**	**N89103 001**	JUL 02, 1985
AB		**25MG**	**N89104 001**	JUL 02, 1985
AB		**50MG**	**N89105 001**	JUL 02, 1985
@		10MG	N89103 001	JUL 02, 1985
@		25MG	N89104 001	JUL 02, 1985
@		50MG	N89105 001	JUL 02, 1985

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

	AKTOB			
AT	AKORN	0.3%	N64096 001	JAN 31, 1996

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE			
AB	BARR	100MG	N70162 001	JAN 14, 1986
AB		250MG	N70163 001	JAN 14, 1986
AB		500MG	N70164 001	JAN 14, 1986
	@	100MG	N70162 001	JAN 14, 1986
	@	250MG	N70163 001	JAN 14, 1986
	@	500MG	N70164 001	JAN 14, 1986
AB	ZENITH GOLDLINE	100MG	N18894 001	NOV 02, 1984
AB		250MG	N18894 002	NOV 02, 1984
AB		500MG	N18894 003	NOV 02, 1984
AB	ZENITH LABS	100MG	N18894 001	NOV 02, 1984
AB		250MG	N18894 002	NOV 02, 1984
AB		500MG	N18894 003	NOV 02, 1984

TOLBUTAMIDE

TABLET; ORAL

	ORINASE			
	@ PHARMACIA AND UPJOHN	500MG	N10670 001	
AB	+ UPJOHN	500MG	N10670 001	
	TOLBUTAMIDE			
AB	BARR	500MG	N87121 001	
	@	500MG	N87121 001	
AB	EON LABS	500MG	N12678 001	
AB	+	500MG	N12678 001	

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE			
AB	SUPERPHARM	500MG	N88893 001	NOV 19, 1984
	@	500MG	N88893 001	NOV 19, 1984

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM			
AB	BAKER NORTON	EQ 600MG BASE	N74399 001	MAR 28, 1996

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

	HYCAMTIN			
	+ SMITHKLINE BEECHAM	EQ 4MG BASE/VIAL	N20671 001	MAY 28, 1996

TRANDOLAPRIL

TABLET; ORAL

	MAVIK			
	KNOLL PHARM	1MG	N20528 001	APR 26, 1996
		2MG	N20528 002	APR 26, 1996
	+	4MG	N20528 003	APR 26, 1996

TRANEXAMIC ACID

TABLET; ORAL

	CYKLOKAPRON			
	+ PHARMACIA	500MG	N19280 001	DEC 30, 1986
	@ PHARMACIA AND UPJOHN	500MG	N19280 001	DEC 30, 1986

TRETINOIN

CREAM; TOPICAL
RENOVA
JOHNSON RW 0.05% N19963 001 DEC 29, 1995

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
KENALOG-H
AT APOTHECON 0.1% N86240 001
@ 0.1% N86240 001

OINTMENT; TOPICAL
ARISTOCORT A
AT LEDERLE 0.5% N80745 003
AT + 0.5% N80745 003
KENALOG
AT + APOTHECON 0.5% N83944 001
@ 0.5% N83944 001

SPRAY, METERED; NASAL
NASACORT AQ
+ RHONE POULENC RORER 0.055MG/INH N20468 001 MAY 20, 1996

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE HCL
HALSEY 1.25MG/5ML N88735 001 JAN 17, 1985
@ 1.25MG/5ML N88735 001 JAN 17, 1985

> ADD > UREA, C-13

> ADD > POWDER FOR RECONSTITUTION; ORAL
> ADD > MERETEK UBT KIT (W/ PRANACTIN)
> ADD > + MERETEK 125MG/VIAL N20586 001 SEP 17, 1996
> ADD >

UROFOLLITROPIN

INJECTABLE; INJECTION
METRODIN
+ SERONO 75 IU/AMP N19415 002 SEP 18, 1986
150 IU/AMP N19415 003 SEP 18, 1986

INJECTABLE; INTRAMUSCULAR
METRODIN
+ SERONO 75 IU/AMP N19415 002 SEP 18, 1986
150 IU/AMP N19415 003 SEP 18, 1986

INJECTABLE; SUBCUTANEOUS
FERTINEX
+ SERONO 75 IU/AMP N19415 005 AUG 23, 1996
150 IU/AMP N19415 004 AUG 23, 1996

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
+ ELAN PHARM 360MG N19614 004 MAY 10, 1996

TABLET; ORAL
VERAPAMIL HCL
AB SIDMAK LABS NJ 40MG N72751 001 FEB 23, 1996

TABLET, EXTENDED RELEASE; ORAL
COVERA-HS
BC SEARLE 180MG N20552 001 FEB 26, 1996
BC 240MG N20552 002 FEB 26, 1996

VERAPAMIL HCL
AB MYLAN 240MG N74587 001 MAR 23, 1996
AB SIDMAK LABS NJ 240MG N72922 001 MAR 01, 1996

VIDARABINE

INJECTABLE; INJECTION

VIRA-A			
+	PARKE DAVIS	EQ 187.4MG BASE/ML	N50523 001
@		EQ 187.4MG BASE/ML	N50523 001

> ADD > ZAFIRLUKAST

> ADD > TABLET; ORAL

> ADD > ACCOLATE

> ADD >	+ ZENECA	20MG	N20547 001
> ADD >			SEP 26, 1996

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER			
+ BAYER	650MG	N16030 001	
+ STERLING	650MG	N16030 001	
MEASURIN			
+ BAYER	650MG	N16030 002	
+ STERLING	650MG	N16030 002	

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK		
+ ENVIRODERM	5%	N20532 001 AUG 26, 1996

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

DIMETANE		
+ ROBINS AH	8MG	N10799 010 JUN 10, 1983
+	12MG	N10799 011 JUN 10, 1983
@ WHITEHALL ROBINS	8MG	N10799 010 JUN 10, 1983
DIMETAPP		
+ WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIMETAPP		
+ ROBINS AH	2MG/5ML;12.5MG/5ML	N13087 003 MAR 29, 1984
+ WHITEHALL ROBINS	2MG/5ML;12.5MG/5ML	N13087 003 MAR 29, 1984

TABLET, EXTENDED RELEASE; ORAL

DIMETAPP		
+ ROBINS AH	12MG;75MG	N12436 003 MAY 14, 1985
+ WHITEHALL ROBINS	12MG;75MG	N12436 003 MAY 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE		
+ ALZA	16MG;240MG	N19672 001 MAR 29, 1996

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12		
CENT PHARMS	12MG;120MG	N18935 001 APR 15, 1985
+	12MG;120MG	N18935 001 APR 15, 1985
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE		
+ CENT PHARMS	8MG;120MG	N19428 001 AUG 02, 1988
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE		
+ GRAHAM	8MG;120MG	N18844 001 MAR 20, 1985
+	12MG;120MG	N18843 001 MAR 18, 1985
@	8MG;120MG	N18844 001 MAR 20, 1985
@	12MG;120MG	N18843 001 MAR 18, 1985
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE		
CENT PHARMS	8MG;120MG	N19428 001 AUG 02, 1988

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CORSYM		
@ FISONS	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001 JAN 04, 1984
@ MEDEVA PHARMS	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001 JAN 04, 1984

CIMETIDINE

TABLET; ORAL
TAGAMET HB
+ SMITHKLINE BEECHAM 100MG N20238 001 JUN 19, 1995
100MG N20238 001 JUN 19, 1995
+ 200MG N20238 002 AUG 21, 1996

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE >ADD<

TABLET, EXTENDED RELEASE; ORAL
TAVIST-D
SANDOZ 1.34MG;75MG N20640 001 AUG 09, 1996

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN 3 COMBINATION PACK
+ SCHERING PLOUGH 1%,200MG N20526 002 JUL 29, 1996

SUPPOSITORY; VAGINAL
GYNE-LOTRIMIN
+ SCHERING PLOUGH 100MG N17717 002 NOV 30, 1990

GYNE-LOTRIMIN 3
+ SCHERING PLOUGH 200MG N20525 001 JUL 29, 1996

MYCELEX-7
BAYER 100MG N18182 002 DEC 26, 1991

TABLET; VAGINAL
GYNE-LOTRIMIN
+ SCHERING PLOUGH 100MG N17717 002 NOV 30, 1990

MYCELEX-7
BAYER 100MG N18182 002 DEC 26, 1991

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
DELSYM
+ FISONS EQ 30MG HBR/5ML N18658 001
+ MEDEVA PHARMS EQ 30MG HBR/5ML N18658 001

DOXYLAMINE SUCCINATE

TABLET; ORAL
DOXYLAMINE SUCCINATE
PERRIGO 25MG N40167 001 SEP 18, 1996 >ADD<

IBUPROFEN

CAPSULE; ORAL
MIDOL
@ BAYER 200MG N70626 001 SEP 02, 1987
@ 200MG N71002 001 SEP 02, 1987
@ WINTHROP 200MG N70626 001 SEP 02, 1987
@ 200MG N71002 001 SEP 02, 1987

PROVEL
+ SANDOZ 200MG N20402 001 APR 20, 1995
@ 200MG N20402 001 APR 20, 1995

SUSPENSION; ORAL
CHILDREN'S ADVIL
WHITEHALL ROBINS 100MG/5ML N20589 001 JUN 27, 1996

SUSPENSION/DROPS; ORAL
CHILDREN'S MOTRIN
+ MCNEIL CONS PRODS 40MG/ML N20603 001 JUN 10, 1996

TABLET; ORAL
IBUPROFEN
HALSEY 200MG N71027 001 SEP 29, 1987

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
@ HALSEY	200MG	N71027 001 SEP 29, 1987
@ LEMMON	200MG	N73141 001 MAY 29, 1992
MCNEIL CONS PRODS	200MG	N73019 001 MAR 30, 1994
+	200MG	N73019 001 MAR 30, 1994
TAG PHARMS	200MG	N73141 001 MAY 29, 1992
JUNIOR STRENGTH MOTRIN		
MCNEIL CONS PRODS	100MG	N20602 001 JUN 10, 1996
MIDOL		
@ BAYER	200MG	N70591 001 SEP 02, 1987
@	200MG	N71001 001 SEP 02, 1987
@ WINTHROP	200MG	N70591 001 SEP 02, 1987
@	200MG	N71001 001 SEP 02, 1987
NUPRIN		
+ BRISTOL MYERS	200MG	N72035 001 FEB 16, 1988
	200MG	N72035 001 FEB 16, 1988

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II		
+ LILLY	100 UNITS/ML	N18478 001
@	100 UNITS/ML	N18478 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN N		
+ NOVO NORDISK	100 UNITS/ML	N19065 001 JAN 23, 1985
@	100 UNITS/ML	N19065 001 JAN 23, 1985

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC INSULIN		
+ SQUIBB	40 UNITS/ML	N17928 001
+	100 UNITS/ML	N17928 003
@	40 UNITS/ML	N17928 001
@	100 UNITS/ML	N17928 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE		
+ NOVO NORDISK	100 UNITS/ML	N18385 001
@	100 UNITS/ML	N18385 001

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE		
+ NOVO NORDISK	100 UNITS/ML	N18382 001
@	100 UNITS/ML	N18382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II		
+ LILLY	100 UNITS/ML	N18477 001
@	100 UNITS/ML	N18477 001

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 7		
NMC	2%	N74164 001 MAR 29, 1996
MICONAZOLE NITRATE		
G AND W LABS	2%	N74366 001 FEB 22, 1996

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT-3 COMBINATION PACK		
+ ADV CARE	2%,200MG	N20670 002 APR 16, 1996

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)			
ALPHARMA	2%	N74588 001	APR 05, 1996
BAUSCH AND LOMB	2%	N74643 001	APR 09, 1996
COPLEY PHARM	2%	N74500 001	MAY 23, 1996
LEMMON	2%	N74589 001	APR 05, 1996
ROGAINE (FOR MEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 002	FEB 09, 1996
ROGAINE (FOR WOMEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 003	FEB 09, 1996

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

OCUHIST			
AKORN	0.025%;0.3%	N20485 001	JAN 31, 1996
OPCON-A			
+ BAUSCH AND LOMB	0.027%;0.315%	N20065 001	JUN 08, 1994
+	0.02675%;0.315%	N20065 001	JUN 08, 1994

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICODERM CQ			
+ HOECHST MARION RSSL	7MG/24HR	N20165 006	AUG 02, 1996
+	14MG/24HR	N20165 005	AUG 02, 1996
+	21MG/24HR	N20165 004	AUG 02, 1996
NICOTROL			
+ MCNEIL CONS PRODS	15MG/16HR	N20536 001	JUL 03, 1996

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE			
+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 002	FEB 09, 1996
+	EQ 4MG BASE	N20066 002	FEB 09, 1996

NIZATIDINE

TABLET; ORAL

AXID AR			
+ WHITEHALL ROBINS	75MG	N20555 001	MAY 09, 1996

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HCL			
+ ALZA	240MG	N20021 002	DEC 15, 1992
+ CIBA	240MG	N20021 002	DEC 15, 1992

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PSEUDO-12			
@ FISONS	EQ 60MG HCL/5ML	N19401 001	JUN 19, 1987
@ MEDEVA PHARMS	EQ 60MG HCL/5ML	N19401 001	JUN 19, 1987

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 9 / SEP '96

NO SEPTEMBER 1996 APPROVALS

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January 1, 1996 thru September 30, 1996]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
-deoxycytidine N=	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D. Massey Cancer Center, VCU P.O. Box 980230 Richmond, VA 23298 DD=09/09/96 MA= / /
-nitro-20-(S)-camptothecin 9-NC) N=	Treatment of pancreatic cancer.	Stehlin Foundation for Cancer Cancer Research 1315 Calhoun, Suite 1818 Houston, TX 77002 DD=09/16/96 MA= / /
photericin B lipid complex N= Abelcet	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=06/27/96 MA= / /
photericin B lipid complex N= Abelcet	Treatment of invasive zygomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
photericin B lipid complex N= Abelcet	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
photericin B lipid complex N= Abelcet	Treatment of invasive prototheçosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=08/21/96 MA= / /
photericin B lipid complex N= Abelcet	Treatment of invasive sporotrichosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=09/23/96 MA= / /
ntihemophilic factor (human) N= Alphanate	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=01/05/96 MA= / /
rcitumomab N= 99m Te-labeled CBA-Scan	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=05/10/96 MA= / /
lostridial collagenase N=	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. Ph.D. State University of New York at Stony Brook School of Medicine Health Sciences Center T18-020 Stony Brook, NY 11794 DD=05/23/96 MA= / /
ollagenase (lyophilized) for njection N= Plaquase	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook, NY 11563 DD=03/12/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
C1-esterase inhibitor (human) TN=	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=08/21/96 MA= / /
DAB3891L-2 TN=	Treatment of cutaneous T-cell lymphoma.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/96 MA= / /
Dihydrotestosterone TN=Androgel-DHT	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
DMP 777 TN=	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	Dupont Merck Pharmaceutical Company Dupont Merck Plaza, Maple Run 2110 Wilmington, DE 19805 DD=06/04/96 MA= / /
Etiocholanedione TN=	Treatment of Prader-Willi syndrome.	SuperGen, Inc. 3158 Des Plains Avenue Suite 10 Des Plains, IL 60018 DD=05/07/96 MA= / /
Gusperimus TN=Spanidin	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb Company 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=06/27/96 MA= / /
Human acid alpha-glucosidase TN=	Treatment of glycogen storage disease type II.	Pharming B.V. Niels Bohrweg 11-13 2333 CA Leiden The Netherlands DD=09/10/96 MA= / /
Indoxuridine TN=	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest, IL 60045 DD=04/08/96 MA= / /
Interferon beta-1a TN=Rebif	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/11/96 MA= / /
Interferon gamma-1b TN=Actimmune	Treatment of severe congenital osteopetrosis.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=09/30/96 MA= / /
KL4-Surfactant TN=	Treatment of meconium aspiration syndrome in newborn infants.	Cochrane, Charles, M.D. The Scripps Research Institute 10666 Torrey Pines Road LaJolla, CA 92037 DD=07/30/96 MA= / /
L-2-oxothiazolidine 4-carboxylic acid TN=Procysteine	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West Cambridge, MA 02139 DD=07/30/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ipid/DNA human cystic ibrosis gene N=	Treatment of cystic fibrosis.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=04/08/96 MA= / /
iposomal prostaglandin E1 njection N=	Treatment of acute respiratory distress syndrome.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=04/25/96 MA= / /
ethionine/L-methionine N=	Treatment of AIDS myelopathy.	DiRocco, Alessandro M.D. The Mount Sinai Medical Center One Gustave L. Levy Place, Box 1139 New York, NY 10029 DD=08/21/96 MA= / /
ethylnaltrexone N=	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	The University of Chicago 5841 South Maryland Avenue MC 4028 Chicago, IL 60637 DD=06/17/96 MA= / /
itoxantrone N=Novantrone	Treatment of hormone refractory prostate cancer.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=08/21/96 MA= / /
itazoxanide N=	Treatment of cryptosporidiosis in HIV-positive and AIDS patients.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=01/05/96 MA= / /
rostaglandin E1 in lipid mulsion N=	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=09/10/96 MA= / /
ifapentine N=	Prophylactic treatment of Mycobacterium avium complex in patients with acquired immunodeficiency syndrome and a CD4+ count less than or equal to 75/mm3.	Marion Merrell Dow Inc. P.O. Box 9627 (Park A) Kansas City, MO 64137 DD=03/12/96 MA= / /
-VIII SQ N= REFACTO	For long-term and/or hospital treatment of hemophilia A or for treatment of patients with hemophilia A in connection with surgical procedures.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo, MI 49001 DD=02/08/96 MA= / /
omatropin for injection N=Serostim	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/26/96 MA= / /
U101 N=	Treatment of ovarian cancer.	Sugen, Inc. 515 Galveston Drive Redwood City, CA 94063 DD=03/12/96 MA= / /
estosterone N=Androgel	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
halidomide N=Synovir	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=03/11/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Uridine 5'triphosphate TN=	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham, NC 27703 DD=06/26/96 MA= / /
Valine, isoleucine and leucine TN=VIL	Treatment of hyperphenylalaninemia.	Leas Research Products 4 Brookview Lane Troy, NY 12180 DD=01/05/96 MA= / /

AME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ORPHAN DRUG PRODUCT APPROVALS FOR 1996		
bendazole = Albenza	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/17/96 MA=06/11/96
lbendazole N= Albenza	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/18/96 MA=06/11/96
llopurinol sodium N= Zyloprim for Injection	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Glaxo Wellcome Inc. Five Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=10/16/92 MA=05/17/96
leomycin sulfate N=Blenoxane	Treatment of malignant pleural effusion.	Bristol-Myers Squibb P.O. Box 4000 Princeton, NJ 08543 DD=09/17/93 MA=02/20/96
ffered intrathecal lectrolyte/dextrose injection N=Elliotts B Solution	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.	Orphan Medical 13911 Ridgedale Drive Minnetonka, MN 55305 DD=08/24/94 MA=09/27/96
rticorelin ovine triflutate N=Acthrel	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern, NY 10901 DD=11/24/89 MA=05/23/96
aunorubicin citrate liposome njection N=DaunoXome	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas, CA 91773 DD=05/14/93 MA=04/08/96
osphenytoin N=	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company 2800 Plymouth Road Ann Arbor, MI 48106 DD=06/04/91 MA=08/05/96
anciclovir intravitreal mplant N=Vitrasert Implant	Treatment of cytomegalovirus retinitis.	Chiron Vision 500 Iolab Drive Claremont, CA 91711 DD=06/07/95 MA=03/04/96
nterferon beta-1a N=Avonex	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=12/16/91 MA=05/17/96
idodrine HCl N=Amatine	Treatment of idiopathic orthostatic hypotension, i.e., Shy-Drager Syndrome, Bradbury-Eggleston Syndrome.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eastontown, NJ 07724 DD=06/21/85 MA=09/06/96

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval

ORPHAN DRUG PRODUCT APPROVALS FOR 1996

Ofloxacin TN=Ocuflox Ophthalmic Solution	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92713 DD=04/18/91 MA=05/22/96
Pentosan polysulfate sodium TN=Elmiron	Treatment of interstitial cystitis.	Baker Norton Pharmaceuticals 4400 Biscayne Boulevard Miami, FL 33137 DD=08/07/85 MA=09/26/96
Polifeprosan 20 with carmustine TN=Gliadel	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc. 6611 Tributary Street Baltimore, MD 21224 DD=12/13/89 MA=09/23/96
Respiratory syncytial virus immune globulin (human) TN=Respigam	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg, MD 20878 DD=09/27/90 MA=01/18/96
Sodium phenylbutyrate TN=Buphenyl	Treatment of urea cycle disorders carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Ucyclyd Pharma 10819 Gilroy Road, Suite 100 Hunt Valley, MD 21031 DD=11/22/93 MA=04/30/96
Somatropin for injection TN=Serostim	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=11/15/91 MA=08/23/96

NO SEPTEMBER

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 1996 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 7500 STANDISH PLACE, ROCKVILLE, MD 20855. COPIES OF THESE GUIDANCES MAY ALSO BE OBTAINED FROM THE DIVISION OF COMMUNICATION MANAGEMENT, CENTER FOR DRUG EVALUATION AND RESEARCH, FDA, 5600 FISHERS LANE (HFD-210) ROCKVILLE, MD 20857 OR BY CALLING (301) 827-4573, FAX: (301) 827-4577.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

CLOZAPINE *IN VITRO* AND *IN VIVO* (TABLET)	NOV 15, 1995	APR 19, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBIANTION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08. 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08,1996
ACETAMINOPHEN; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 5MG	95 P-0278/ CP1	MIKART	NEW STRENGTH	APPROVED MAY 28, 1996
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 5MG BASE/ML (100ML/CONTAINER) (200ML/CONTAINER)	95 P-0268/ CP1	WILMER, CUTLER, & PICKERING	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ASPIRIN; BUTALBITAL CAPSULE; ORAL	650MG 50MG	96 P-0021/ CP1	SAVAGE	NEW DOSAGE FORM	APPROVED APR 19, 1996
ATRACURIUM BESYLATE INJECTABLE; INJECTION	0.5MG/ML 1MG/ML (100ML CONTAINER)	95 P-0372/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAR 08, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 100MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 250MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CHOLESTYRAMINE TABLET, CHEWABLE; ORAL ORAL	EQ 2GM RESIN	95 P-0277/ CP1	MAYRAND	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
CYTARABINE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (5ML/VIAL)	92 P-0183/ CP1	FAULDING	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUL 26, 1996
CYTARABINE INJECTABLE; INJECTION	100MG/ML (10ML/VIAL) (20ML/VIAL)	92 P-0184/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUL 26, 1996
DILTIAZEM HYDROCHLORIDE INJECTABLE, INJECTION	5MG/ML (25ML/SYRINGE) (50ML/SYRINGE)	95 P-0196/ CP1	INTL MEDICATION	NEW STRENGTH	APPROVED FEB 27, 1996
EPINEPHRINE INJECTABLE; SUBCUTANEOUS	0.3MG/DELIVERY	95 P-0190/ CP1	SENETCK PLC	NEW ROUTE OF ADMINISTRATION	APPROVED FEB 15, 1996
ETOPOSIDE CAPSULE; ORAL	25MG	95 P-0142/ CP1	GUIDELINES	NEW STRENGTH	APPROVED SEP 12, 1996
HYDROCORTISONE BUTYRATE LOTION; TOPICAL	0.1%	95 P-0223/ CP1	MCKENNA & CUNEO	NEW DOSAGE FORM	APPROVED FEB 21, 1996
LACTULOSE CRYSTALS, FOR RECONSTITUTION; ORAL	20GM/PACKET	95 P-0287/ CP1	BENNETT	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 19, 1996
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (60ML/SYRINGE)	95 P-0348/ CP1	MALLINCKRODT	NEW STRENGTH	APPROVED MAR 08, 1996
METRONIDAZOLE LOTION; TOPICAL	0.75%	95 P-0328/ CP1	RNB PHARM	NEW DOSAGE FORM	APPROVED FEB 23, 1996
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	95-P-0326/ CP1	KV	NEW DOSAGE FORM	APPROVED FEB 23, 1996
PACLITAXEL INJECTABLE; INJECTION	6MG/ML (16.7ML/VIAL) (33.3ML/VIAL) (50ML/VIAL)	95 P-0360/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 29, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
PENTOXIFYLLINE SUSPENSION, EXTENDED RELEASE; ORAL	400MG/PACKET	96 P-0079/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 13, 1996
POTASSIUM CHLORIDE SUSPENSION, EXTENDED RELEASE; ORAL	10MEQ	96 P-0054/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 19, 1996
POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE; ORAL	20MEQ	96 P-0018/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 19, 1996

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCODONE BITRATRATE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION; ORAL	2.5MG/5ML 5MG/5ML	95 P-0336/ CP1	BOCK PHARMA	NEW COMBINATION	DENIED AUG 19, 1996
HYDROCODONE BITRATRATE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION; ORAL	5MG/5ML 10MG/5ML	95 P-0336/ CP2	BOCK PHARMA	NEW COMBINATION	DENIED AUG 19, 1996

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS
D-30 5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS

NEW INDICATION

I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145 0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE ($AaDO_2$) iS LESS THAN OR EQUAL TO 55 TORR
I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163 TREATMENT OF PHOTOPHOBIA
I-164 CHRONIC BACTERIAL PROSTATITIS

PATENT USE CODE

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATING NEUROGENERATIVE DISEASES

EXCLUSIVITY TERMS

PATENT USE CODE

U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHODS FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}CO_2$
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 26, 2008	U-93		
	20338 001	ADAPALENE; DIFFERIN	4717720	APR 10, 2006	U-134	NCE	MAY 31, 2001
	20380 001	ADAPALENE; DIFFERIN	4717720	APR 10, 2006	U-134	NCE	MAY 31, 2001
	20666 001	ALBENDAZOLE; ALBENZA				ODE	JUN 11, 2003
						NCE	JUN 11, 2001
>ADD>	20503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	5225183	JUL 06, 2010			
	20298 001	ALLOPURINOL SODIUM; ZYLOPRIM				NDF	MAY 17, 1999
						ODE	MAY 17, 2003
	20221 001	AMIFOSTINE; ETHYOL				I-149	MAR 15, 1999
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	20508 001	AMMONIUM LACTATE; LAC-HYDRIN				NDF	AUG 29, 1999
	20541 001	ANASTROZOLE; ARIMIDEX	4935437	JUN 10, 2008			
	20428 001	AZELAIC ACID; AZELEX	4386104	MAY 31, 2000	U-124		
	20075 001	BACLOFEN; LIORESAL				I-153	JUN 14, 1999
	20075 002	BACLOFEN; LIORESAL				I-153	JUN 14, 1999
	20469 001	BECLOMETHASONE DIPROPIONATE MONOHYDRATE; VANCENASE AQ				NP	JUN 26, 1999
	20532 001	BENTOQUATAM; IVY BLOCK				NCE	AUG 26, 2001
	20498 001	BICALUTAMIDE; CASODEX	4636505	JAN 13, 2004			
	50443 001	BLEOMYCIN SULFATE; BLENOXANE				ODE	FEB 20, 2003
>ADD>	20613 001	BRIMONIDINE TARTRATE; ALPHAGAN				NCE	SEP 06, 2001
	19672 001	BROMPHENIRAMINE MALEATE; EFIDAC 24	4810502	MAR 14, 2006			
			4801461	MAR 14, 2006			
			4673405	MAR 18, 2003			
			4662880	MAR 14, 2006		NP	MAR 29, 1999
>ADD>	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
			4182763	MAY 22, 2000	U-13		
>ADD>	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
			4182763	MAY 22, 2000	U-13		
>ADD>	18731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
>ADD>			4182763	MAY 22, 2000	U-13		
>ADD>	18731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
>ADD>			4182763	MAY 22, 2000	U-13		
	19215 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	MAR 07, 1997			
	19359 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	MAR 07, 1997			
	20421 001	BUTOCONAZOLE NITRATE; FEMSTAT 3	4078071	MAR 07, 1997		NP	DEC 21, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20273 001	CALCIPOTRIENE; DOVONEX	4866048	DEC 29, 2007	U-88	NCE	DEC 29, 1998
	20554 001	CALCIPOTRIENE; DOVONEX	4866048	SEP 12, 2006		NDF	JUL 22, 1999
	18874 001	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
	18874 002	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
	18343 004	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
						I-101	JAN 28, 1997
	18343 007	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
						I-101	JAN 28, 1997
	20234 001	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
	20234 002	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
	20234 003	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
>ADD>	20637 001	CARMUSTINE; GLIADEL				NP	AUG 23, 1999
>ADD>						ODE	AUG 23, 2003
	19835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002			
	19835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002			
>ADD>	20346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002		NDF	DEC 27, 1999
>ADD>						NCE	DEC 08, 2000
	20638 001	CIDOFOVIR; VISTIDE	5142051	AUG 25, 2009		NCE	JUN 26, 2001
	19537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
>ADD>						I-164	SEP 11, 1999
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
>ADD>						I-164	SEP 11, 1999
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
>ADD>						I-164	SEP 11, 1999
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
>ADD>						I-164	SEP 11, 1999
	20398 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20551 001	CISATRACURIUM BESYLATE; NIMBEX	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
	20551 002	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20551 003	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
>ADD>	18057 001	CISPLATIN; PLATINOL	5562925	MAY 08, 2012			
>ADD>	18057 002	CISPLATIN; PLATINOL	5562925	MAY 08, 2012			
>ADD>	18057 004	CISPLATIN; PLATINOL-AQ	5562925	MAY 08, 2012			
	20340 001	CLOBETASOL PROPIONATE; TEMOVATE E				D-32	MAY 03, 1999
	20525 001	CLOTRIMAZOLE; GYNE-LOTRIMIN 3				NP	JUL 29, 1999
	20526 002	CLOTRIMAZOLE; GYNE-LOTRIMIN 3 COMBINATION PACK				NP	JUL 29, 1999
	20162 001	CORTICORELIN OVINE TRIFLUTATE; ACTHREL				NCE	MAY 23, 2001
	20479 001	CROMOLYN SODIUM; GASTROCROM	4515805	MAY 07, 2002	U-130		
			4421762	DEC 20, 2000	U-130		
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2005		NCE	DEC 22, 1999
						D-30	MAR 18, 1999
	20287 003	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2005		NCE	DEC 22, 1999
						D-30	MAR 18, 1999
	50704 002	DAUNORUBICIN CITRATE; DAUNOXOME				ODE	APR 08, 2003
	20118 001	DESFLURANE; SUPRANE	4762856	FEB 02, 2007	U-67	NCE	SEP 18, 1997
	19955 001	DESMOPRESSIN ACETATE; DDAVP	5047398	SEP 10, 2008			
	19955 002	DESMOPRESSIN ACETATE; DDAVP	5047398	SEP 10, 2008			
	20071 001	DESOGESTREL; DESOGEN	3927046	NOV 19, 1995			
	20071 002	DESOGESTREL; DESOGEN	3927046	NOV 19, 1995			
	20301 001	DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995			
	20301 002	DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995			
	20344 001	DEXFENFLURAMINE HYDROCHLORIDE; REDUX	4309445	JUN 16, 2000	U-133		
>ADD>	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960799	OCT 02, 2007		I-163	JUL 23, 1999
	20254 001	DICLOFENAC SODIUM; VOLTAREN-XR				NDF	MAR 08, 1999
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20401 001	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 002	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 003	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 004	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 005	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013		NS	SEP 11, 1998
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20449 001	DOCETAXEL; TAXOTERE	5403858	JUL 03, 2012			
			4814470	JUL 14, 2007		NCE	MAY 14, 2001
	20164 001	ENOXAPARIN SODIUM; LOVENOX	5389618	FEB 14, 2012			
			4692435	DEC 24, 2004	U-123		
			4486420	DEC 04, 2001	U-122		
	20472 001	ESTRADIOL; ESTRING				NDF	APR 26, 1999
>ADD>	20538 001	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011		NS	OCT 28, 1997
>ADD>			4994278	MAR 04, 2008			
>ADD>			4994267	MAR 04, 2008			
>ADD>			4814168	MAR 04, 2008			
>ADD>	20538 002	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011			
>ADD>			4994278	MAR 04, 2008			
>ADD>			4994267	MAR 04, 2008			
>ADD>			4814168	MAR 04, 2008			
>ADD>	20538 003	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011		NS	OCT 28, 1997
>ADD>			4994278	MAR 04, 2008			
>ADD>			4994267	MAR 04, 2008			
>ADD>			4814168	MAR 04, 2008			
>ADD>	20538 004	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011			
>ADD>			4994278	MAR 04, 2008			
>ADD>			4994267	MAR 04, 2008			
>ADD>			4814168	MAR 04, 2008			
	18922 002	ETODOLAC; LODINE				I-24	JUN 28, 1999
	18922 003	ETODOLAC; LODINE				I-24	JUN 28, 1999
	18922 004	ETODOLAC; LODINE				I-24	JUN 28, 1999
	20457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS	5041424	AUG 20, 2008	U-135		
			4904768	FEB 27, 2007		NE	MAY 17, 1999
	20195 001	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20195 002	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20195 003	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20195 007	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20416 001	FERUMOXIDES; FERIDEX I.V.	5248492	SEP 28, 2010		NCE	AUG 30, 2001
			5219554	JUN 15, 2010			
			5102652	FEB 06, 2009			
			5055288	OCT 08, 2008			
			4951675	AUG 28, 2007	U-143		
			4827945	MAY 09, 2006	U-144		
			4770183	SEP 13, 2005	U-145		
	20625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5375693	AUG 03, 2012	U-138	NCE	JUL 25, 2001
			4254129	APR 10, 1999	U-139		
	20548 001	FLUTICASONE PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
	20548 002	FLUTICASONE PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
	20548 003	FLUTICASONE PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
	20261 001	FLUVASTATIN SODIUM; LESCOL				D-31	MAR 20, 1999
	20261 002	FLUVASTATIN SODIUM; LESCOL				D-31	MAR 20, 1999
>ADD>	20450 001	FOSPHENYTOIN SODIUM; CEREBYX	4925860	AUG 05, 2007			
			4260769	APR 07, 1998		NCE	AUG 05, 2001
	20235 001	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20235 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20235 003	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20123 001	GADODIAMIDE; OMNISCAN	4687659	MAY 04, 2007		D-29	FEB 05, 1999
						I-145	FEB 05, 1999
						I-144	FEB 05, 1999
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		I-146	FEB 28, 1999
>ADD>	20569 001	GANCICLOVIR; VITRASERT				NP	MAR 04, 1999
>DLT>						~~NP~~	~~MAR 04, 1996~~
						ODE	MAR 04, 2003
>ADD>	20509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	5464826	NOV 07, 2012	U-146		
>ADD>			4808614	FEB 28, 2006		NCE	MAY 15, 2001
>ADD>	20509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	5464826	NOV 07, 2012	U-146		
>ADD>			4808614	FEB 28, 2006		NCE	MAY 15, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20329 001	GLIPIZIDE; GLUCOTROL XL	5545413	JUL 02, 2008	U-150		
>ADD>			5082668	SEP 16, 2003			
>DLT>			~~5082668~~	~~JAN 21, 2009~~			
>ADD>	20329 002	GLIPIZIDE; GLUCOTROL XL	5545413	JUL 02, 2008	U-150		
>ADD>			5082668	SEP 16, 2003			
>DLT>			~~5082668~~	~~JAN 21, 2009~~			
	19726 001	GOSERELIN ACETATE; ZOLADEX	5366734	NOV 22, 2011			
			4767628	AUG 30, 2005		I-88	FEB 02, 1996
	20578 001	GOSERELIN ACETATE; ZOLADEX	5366734	NOV 22, 2011			
			4767628	AUG 30, 2005			
			4100274	APR 22, 1999		NP	JAN 11, 1999
	20239 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-89		
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-105		
	19836 001	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	19836 002	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	19836 003	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	20589 001	IBUPROFEN; CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
	20602 001	IBUPROFEN; JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
	20603 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
	20685 001	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
	20685 003	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
	20563 001	INSULIN LISPRO; HUMALOG	5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
	20351 001	IODIXANOL; VISIPAQUE 270	5349085	SEP 20, 2011		NCE	MAR 22, 2001
			4396597	JUL 03, 1999			
			4278654	JUL 03, 1999			
	20351 002	IODIXANOL; VISIPAQUE 320	5349085	SEP 20, 2011		NCE	MAR 22, 2001
			4396597	JUL 03, 1999			
			4278654	JUL 03, 1999			
	18735 001	IOPAMIDOL; ISOVUE-M 200	4001323	JAN 04, 1996			
	18735 002	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
	18735 003	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996		D-28	MAY 15, 1998
	18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	JAN 04, 1996			
	18735 007	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			
	20327 001	IOPAMIDOL; ISOVUE-200	4001323	JAN 04, 1996			
	20327 002	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			
	20327 003	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
	20327 004	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463	JUL 05, 2004		NCE	JUN 14, 2001
20083 001	ITRACONAZOLE; SPORANOX				I-155	SEP 28, 1998
19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55		
19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
19700 001	KETOROLAC TROMETHAMINE; ACULAR	4089969	MAY 16, 1997	U-75		
20564 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
20596 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20406 001	LANSOPRAZOLE; PREVACID	4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
20406 002	LANSOPRAZOLE; PREVACID	4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
20597 001	LATANOPROST; XALATAN				NCE	JUN 05, 2001
20517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5480656	JAN 02, 2013			
20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	DEC 07, 2004		NCE	NOV 10, 1998
20575 001	LIDOCAINE; LIDOCAINE	5446070	FEB 27, 2011			
		5332576	JUL 26, 2011			
		5234957	FEB 27, 2011		NDF	MAY 21, 1999
20575 002	LIDOCAINE; LIDOCAINE	5446070	FEB 27, 2011			
		5332576	JUL 26, 2011			
		5234957	FEB 27, 2011		NDF	MAY 21, 1999
19558 001	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
19558 002	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
19558 003	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
19558 004	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
19558 006	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
19777 001	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 002	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 003	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 004	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 005	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
19658 001	LORATADINE; CLARITIN	4659716	APR 21, 2004	U-142	I-136	SEP 20, 1998
19670 001	LORATADINE; CLARITIN-D	4659716	APR 21, 2004	U-142	NC	NOV 14, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20470 001	LORATADINE; CLARITIN-D 24 HOUR	5314697	OCT 23, 2012			
			4659716	APR 21, 2004	U-142	NP	AUG 23, 1999
	19940 001	MASOPROCOL; ACTINEX	4282233	JUL 19, 2002	U-77	NCE	APR 12, 1998
	19651 001	MESALAMINE; ASACOL	4695590	APR 17, 2008			
			5541171	JUL 30, 2013	U-141		
	20208 001	METRONIDAZOLE; METROGEL-VAGINAL	5541170	JUL 30, 2013	U-141		
	20670 002	MICONAZOLE NITRATE; MONISTAT-3 COMBINATION PACK	5536743	JUL 16, 2013	U-137		
>ADD>	19815 001	MIDODRINE HYDROCHLORIDE; PROAMATINE				NP	APR 16, 1999
>ADD>	19815 002	MIDODRINE HYDROCHLORIDE; PROAMATINE				NCE	SEP 06, 2001
	20415 001	MIRTAZAPINE; REMERON				NCE	SEP 06, 2001
	20415 002	MIRTAZAPINE; REMERON				NCE	JUN 14, 2001
	20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC				NCE	JUN 14, 2001
	20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4344949	OCT 03, 2000			
	20616 001	MORPHINE SULFATE; KADIAN	4344949	OCT 03, 2000			
			5378474	MAR 23, 2010			
	20616 002	MORPHINE SULFATE; KADIAN	5202128	APR 13, 2010		NDF	JUL 03, 1999
			5378474	MAR 23, 2010			
	20616 003	MORPHINE SULFATE; KADIAN	5202128	APR 13, 2010		NDF	JUL 03, 1999
			5378474	MAR 23, 2010			
	19886 001	NAFARELIN ACETATE; SYNAREL	5202128	APR 13, 2010		NDF	JUL 03, 1999
	20353 001	NAPROXEN SODIUM; NAPRELAN	4234571	JUN 11, 2011			
	20353 002	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20353 003	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE				NDF	JAN 05, 1999
	20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20636 001	NEVIRAPINE; VIRAMUNE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	19488 001	NICARDIPINE HYDROCHLORIDE; CARDENE	5366972	NOV 22, 2011		NCE	JUN 21, 2001
	19488 002	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
	19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
	20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995			
	20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995			
	20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20165 001	NICOTINE; NICODERM	5508038	APR 16, 2013			
	20165 002	NICOTINE; NICODERM	5508038	APR 16, 2013			
	20165 003	NICOTINE; NICODERM	5508038	APR 16, 2013			
	20385 001	NICOTINE; NICOTROL				NP	MAR 22, 1999
>ADD>	18612 002	NICOTINE POLACRILEX; NICORETTE				NP	FEB 09, 1999
>ADD>	20066 002	NICOTINE POLACRILEX; NICORETTE				NP	FEB 09, 1999
>ADD>	20169 001	NILUTAMIDE; NILANDRON				NCE	SEP 19, 2001
	20555 001	NIZATIDINE; AXID AR				NS	MAY 09, 1999
	19921 001	OFLOXACIN; OCUFLOX				ODE	MAY 22, 2003
						I-160	MAY 22, 1999
>ADD>	20592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
>ADD>	20592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
>ADD>	20592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
>ADD>	20592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
	19810 001	OMEPRAZOLE; PRILOSEC	4255431	APR 05, 2001	U-108	I-23	MAR 22, 1999
	19810 003	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108	I-23	MAR 22, 1999
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN				I-151	MAY 16, 1999
	18841 004	OXAPROZIN; DAYPRO				NCE	OCT 29, 1999*
	20553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	FEB 05, 2008			
			5266331	FEB 05, 2008		NDF	DEC 12, 1998
	20553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	FEB 05, 2008			
			5266331	FEB 05, 2008		NDF	DEC 12, 1998
	20553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	FEB 05, 2008			
			5266331	FEB 05, 2008		NDF	DEC 12, 1998
>ADD>	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996		I-158	JUL 16, 1999
>DLT>			~~3962432~~	~~NOV 09, 1998~~			
>ADD>	20036 003	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996		I-158	JUL 16, 1999
>DLT>			~~3962432~~	~~NOV 09, 1998~~			
>ADD>	20036 004	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996		I-158	JUL 16, 1999
>DLT>			~~3962432~~	~~NOV 09, 1998~~			
	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999

* - In accordance with section 2105(c) of the FDA Export Reform and Enhancement Act of 1996 (Public Law 104-134)

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20629 001	PENCICLOVIR; DENAVIR	5075445	DEC 24, 2008		NCE	SEP 24, 2001
	19887 002	PENTAMIDINE ISETHIONATE; NEBUPENT				I-148	MAR 05, 1999
>ADD>	20193 001	PENTOSAN POLYSULPHATE SODIUM; ELMIRON				NCE	SEP 26, 2001
>ADD>						ODE	SEP 26, 2003
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20451 001	PORFIMER SODIUM; PHOTOFRIN	5438071	AUG 01, 2012			
			5145863	JUN 12, 2007	U-129	ODE	DEC 27, 2002
			5028621	MAR 10, 2004			
			4932934	JUN 12, 2007	U-128	NCE	DEC 27, 2000
			4866168	MAR 10, 2004			
			4649151	MAR 10, 2004			
	19898 005	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008			
			5030447	JUL 09, 2008		I-159	JUL 02, 1999
			4346227	OCT 20, 2005		I-152	MAR 22, 1999
	19898 006	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008			
			5030447	JUL 09, 2008		I-159	JUL 02, 1999
			4346227	OCT 20, 2005		I-152	MAR 22, 1999
	19898 007	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008		I-159	JUL 02, 1999
			5030447	JUL 09, 2008			
			4346227	OCT 20, 2005		I-152	MAR 22, 1999
	20279 001	PREDNICARBATE; DERMATOP				I-154	MAY 03, 1999
	20545 001	PROCAINAMIDE HYDROCHLORIDE; PROCANBID				NP	JAN 31, 1999
	20545 002	PROCAINAMIDE HYDROCHLORIDE; PROCANBID				NP	JAN 31, 1999
>ADD>	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996		I-90	MAR 08, 1996
>DLT>	~~19627 001~~	~~PROPOFOL; DIPRIVAN~~	~~4056635~~	~~NOV 01, 2006~~		~~I-90~~	~~MAR 08, 1996~~
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	20559 001	RANITIDINE BISMUTH CITRATE; TRITEC	5008256	JUL 17, 2009		NE	AUG 08, 1999
	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	20520 001	RANITIDINE HYDROCHLORIDE; ZANTAC 75	4880636	MAY 13, 2008			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	20630 001	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5019583	FEB 15, 2009		NCE	JUL 12, 2001
	20630 002	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5019583	FEB 15, 2009		NCE	JUL 12, 2001
	20630 003	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5019583	FEB 15, 2009		NCE	JUL 12, 2001
	20272 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 002	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 003	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 004	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 005	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20588 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90	NCE	DEC 29, 1998
	20659 001	RITONAVIR; NORVIR	5541206	JUL 30, 2013	U-140		
			5484801	JAN 28, 2014		NCE	MAR 01, 2001
	20680 001	RITONAVIR; NORVIR	5541206	JUL 30, 2013	U-140	NCE	MAR 01, 2001
>ADD>	20533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
>ADD>			4695576	SEP 22, 2004			
>ADD>	20533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
>ADD>			4695576	SEP 22, 2004			
>ADD>	20533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
>ADD>			4695576	SEP 22, 2004			
>ADD>	20533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
>ADD>			4695576	SEP 22, 2004			
	20628 001	SAQUINAVIR MESYLATE; INVIRASE	5196438	NOV 19, 2010			
	20572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
	20573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
						ODE	APR 30, 2003
	19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				I-161	AUG 01, 1999
	19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				I-161	AUG 01, 1999
	20280 004	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
	20280 006	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
	20604 001	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				ODE	AUG 23, 2003
						NP	AUG 23, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20604 002	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				ODE	AUG 23, 2003
					NP	AUG 23, 1999
20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20412 001	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 002	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 003	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 004	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 005	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20256 001	TECHNETIUM TC-99M BICISATE KIT; NEUROLITE	5279811	NOV 23, 2008	U-101	NCE	NOV 23, 1999
19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE				I-142	DEC 14, 1998
20372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEW	5045302	APR 10, 2007		NCE	FEB 09, 2001
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20539 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73	NDF	MAY 10, 1999
					NCE	DEC 30, 1999
20489 001	TESTOSTERONE; ANDRODERM	5164190	NOV 17, 2008			
		5152997	OCT 06, 2009			
		4983395	JAN 08, 2009			
		4863970	SEP 05, 2006			
		4855294	AUG 08, 2006			
		4849224	JUL 18, 2006		NS	SEP 29, 1998
20671 001	TOPOTECAN HYDROCHLORIDE; HYCAMTIN	5004758	APR 02, 2008		NCE	MAY 28, 2001
>ADD> 20136 001	TORSEMIDE; DEMADEX	RE30633	APR 19, 1999			
>DLT> ~~20136 001~~	~~TORSEMIDE; DEMADEX~~	~~RE30633~~	~~APR 19, 1994~~			
>ADD> 20136 002	TORSEMIDE; DEMADEX	RE30633	APR 19, 1999			
>DLT> ~~20136 002~~	~~TORSEMIDE; DEMADEX~~	~~RE30633~~	~~APR 19, 1994~~			
>ADD> 20136 003	TORSEMIDE; DEMADEX	RE30633	APR 19, 1999			
>DLT> ~~20136 003~~	~~TORSEMIDE; DEMADEX~~	~~RE30633~~	~~APR 19, 1994~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20136 004	TORSEMIDE; DEMADEX	RE30633	APR 19, 1999			
>DLT>	~~20136 004~~	~~TORSEMIDE; DEMADEX~~	~~RE30633~~	~~APR 19, 1994~~			
>ADD>	20137 002	TORSEMIDE; DEMADEX	RE30633	APR 19, 1999			
>DLT>	~~20137 002~~	~~TORSEMIDE; DEMADEX~~	~~RE30633~~	~~APR 19, 1994~~			
	20528 001	TRANDOLAPRIL; MAVIK				NCE	APR 26, 2001
	20528 002	TRANDOLAPRIL; MAVIK				NCE	APR 26, 2001
	20528 003	TRANDOLAPRIL; MAVIK				NCE	APR 26, 2001
	19963 001	TRETINOIN; RENOVA	4877805	OCT 31, 2006	U-131		
			4603146	JUL 29, 2003	U-131	NP	DEC 29, 1998
			4423041	DEC 27, 2000			
>ADD>	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	JAN 23, 2007	U-85	I-162	MAY 20, 1999
	19415 002	UROFOLLITROPIN; METRODIN				NR	AUG 23, 1999
	19415 003	UROFOLLITROPIN; METRODIN				NR	AUG 23, 1999
	19594 002	URSODIOL; ACTIGALL				I-147	MAR 29, 1999
>ADD>	20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	AUG 05, 2008		I-143	DEC 15, 1998
>DLT>	~~20487 001~~	~~VALACYCLOVIR HYDROCHLORIDE; VALTREX~~	~~4957924~~	~~SEP 18, 2007~~			
>ADD>	20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	AUG 05, 2008		I-143	DEC 15, 1998
>DLT>	~~20487 001~~	~~VALACYCLOVIR HYDROCHLORIDE; VALTREX~~	~~4957924~~	~~SEP 18, 2007~~			
	20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
	20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
	20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
	20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
	20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
	20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
	20552 001	VERAPAMIL HYDROCHLORIDE; COVERA-HS	5252338	JUN 27, 2011		NP	FEB 26, 1999
			5190765	AUG 14, 2007			
			5160744	JUN 27, 2011			
			4753802	MAR 19, 2006			
	20552 002	VERAPAMIL HYDROCHLORIDE; COVERA-HS	5252338	JUN 27, 2011		NP	FEB 26, 1999
			5190765	AUG 14, 2007			
			5160744	JUN 27, 2011			
			4753802	MAR 19, 2006			
>ADD>	20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	JUL 07, 2002		NCE	DEC 23, 1999
>DLT>	~~20388 001~~	~~VINORELBINE TARTRATE; NAVELBINE~~	~~4307100~~	~~AUG 20, 1999~~		~~NCE~~	~~DEC 23, 1999~~

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20547 001	ZAFIRLUKAST; ACCOLATE	5482963	JAN 09, 2013			
>ADD>			5319097	DEC 11, 2011			
>ADD>			5294636	DEC 11, 2011			
>ADD>			4859692	AUG 22, 2006		NCE	SEP 26, 2001

*U.S. Government Printing Office: 1996 — 417-599/40003

*U.S. Government Printing Office: 1996 — 417-599/40003

New 17th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7971

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/95)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.